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ABBREVIATIONS 
 
FNA   – Fine needle aspiration 
FNAC   – fine needle aspiration cytology 
H & E   – hematoxylin and eosin 
IHC    – Immunohistochemistry 
HPF    – high power field 
TRIS   – tris (hydroxymethyl)amino methane 
WHO  - world health organisation 
TG   - thyroglobulin 
T3    – triiodothyronine 
T4   - thyroxine 
TSH   - thyroid stimulating hormone 
TRH   - thyrotropin releasing hormone  
DPX   - distrene pthalide in xylene 
SV 40  - simian virus 40 
MW   - molecular weight 
KDa   - kiloDalton 
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Wt p53  - wild type p53 
HPE    – histopathology 
PTC    – papillary carcinoma thyroid 
HTA   - hyalinising trabecular adenoma 
Min    – minutes 
 LI    –  labelling index 
M   - Male 
F   - Female 
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INTRODUCTION 
The thyroid gland (Greek, Thyreos – Shield + eidos - Form )24  is a 
butterfly shaped organ situated in anterioinferior region of neck. It is 
composed of two lobes joined together by isthmus. As it is superficially 
located, any pathological changes resulting in enlargement of the gland 
create masses that can be palpable or easily visible. The functional effects 
of hormonal changes also create different clinical manifestations that 
prompt investigation20. 
The Incidence of thyroid nodules constitute about 4-7% of adult 
population. Only 5% of these nodules are malignant and remaining are 
either nonneoplastic or benign21. Thyroid malignancies constitute about 
1.5%70 of all cancers and are more common among Females.  
Fine Needle Aspiration (FNA) is a cost effective and more reliable 
test for diagnosing thyroid Nodules22. Inorder to avoid unneccessary 
surgery38, preoperative distinction between non neoplastic, benign and 
malignant lesions are of utmost importance23. FNA is a serves as a useful 
tool to categorise non neoplastic and neoplastic lesions and thereby guide 
in therapy. It is also helpful in diagnosing and monitoring clinically 
equivocal cases and cases where biochemical and immunological 
parameters are normal or marginally abnormal.  
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Most of the thyroid tumors are readily diagnosed by using 
definitive histological criteria, but there are certain conditions like 
variants of carcinomas derived from follicular epithelial cells where this 
distinction becomes subtle. For this reason ancillary technique like 
immunohistochemistry is used. 
In this study first we analyse cytological and histopathological 
correlation in thyroid lesions. Furthermore the study also evaluates the 
role of immunohistochemical analysis for differentiating benign and 
malignant tumours by using immunological markers. 
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AIMS AND OBJECTIVES 
v To study the incidence of thyroid lesions. 
v To study the age, sex and clinical presentations of thyroid lesions. 
v To assess the cytological and histological correlation of thyroid 
lesion. 
v To estimate the incidence of p53 positivity and Ki-67 index in 
Thyroid malignancies 
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REVIEW OF LITERATURE 
The thyroid gland is a butterfly shaped endocrine gland 
situated in the anterior aspect of the root of the neck.  Disorders of 
thyroid comprise a group of commonly encountered endocrinologic 
disease.  
STUDIES DONE EARLIER: 
History of FNAC: 
 The importance of scientific contribution in medicine 
requires both synthesis of a number of observations and the elixir of 
time. The ultimate acceptance of medical facts and development of 
medical procedures are influenced by social and economic factors. 
The history of fine needle aspiration biopsy was also influenced by 
such factors. The roots of FNAC can be traced back to Scandinavian 
countries. 
 The British Medical Journal “Lancet” in 1833 first reported 
the use of aspiration by aspirating large liver mass at St. 
Bartholomeus Hospital in London by Edward Stanley.  The mass 
was found to be a hydatid cyst and not a tumour 1. 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
  
15 
 In 1847 & 1851 Kun and Lebert described the use of a cannula 
to extract cell samples from palpable tumours and they also 
explained microscope can be used to identify cell morphology 5.  
 In 1853 James Paget in his lectures advocated aspiration forms 
a basic means of diagnosing the lesions. 
 In 1863, Pritchard used grooved needle for aspiration in breast 
lesion. He also gave an excellent description for cytology of fat 
necrosis7 
 Dungeon and Patrick, in 1927, emphasied scrape or touch 
preparation as cytological method to tissue biopsy, which is 
essentially a duplicate of the typical method used in fine needle 
aspiration. They reported 200 cases with accuracy of 98.6%3. 
 The major impact in the development of aspiration biopsy was 
given by two physicians in Sweden and Newyork . Their diagnostic 
methods combined both cytologic and histologic features from cell 
block preparation. 
 In 1926 Martin & Ellis introduced the method of aspiration in 
diagnosis of tumours at memorial Hospital, New York 2.  In 1933 
Steward by studying 45 cases, he felt that the procedure was useful 
in diagnosing anaplastic carcinoma but ambiguous for the 
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differentiating papillary and follicular carcinoma from colloid 
nodules 3. 
 Stewert analysed 2500 tumours in Memorial hospital by aspiration 
method and emphasied certain points to be considered for optimal results. 
They are: 
Ø Technique of aspiration and preparation of the sample. 
Ø Aspirated material should be interpretated along with clinical 
information. 
Ø Compare the picture of the smear with conventional 
histology. 
Ø Pattern of the smear should be taken into consideration along 
with detailed individual cytological features for correct 
interpretation. 
Ø Limitations of aspiration biosy is also taken into 
consideration along with usefulness of this method. 
Lipton and Abel in 1947, measured aspirated cells to evaluate 
hyperthyroidism. Tempka and his associates studied aspirates from 
colloid goiter in 1948. 
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 Soderstom (1952); Eihorn & Franzen (1962) & Cohen & Choi 
(1988) evaluated importance of FNAC in selecting the patients for 
surgical or medical management 3. 
 Mazzaferri EL stated that FNAC is an important diagnostic 
tool for evaluation of a palpable thyroid mass 4. 
The first international course in aspiration cytology was held 
in the year 1970 in Stockholm by Karolinska cytologists. 
 Frable WJ (1989) used small needles (25G or higher gauge) 
for aspiration of thyroid nodules and he also preferred plain slides 
instead of frosted slides for smear making. He used papanicolaou, 
May Grunwald Giemsa (MGG), Metachrome B and hematoxylin 
Eosin stains5. 
In 1988, Non-aspiration fine needle cytology, a new technique 
was pioneered in France to study the nodular thyroid disease. This 
technique employs insertion of the syringe and eliminates active 
aspiration which is replaced by the principle of capillary suction of 
fluid or semisolid material into the hub of the needle 92. 
 Harach HR in 1989 studied 142 cases of nodular goiters and he 
classified follicular lesions into type I (benign) type II (atypical 
benign) and typeIII(suspicious for malignancy) 7. These observations 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
  
18 
along with increase of surgically resected specimens indicated 
FNAC as accurate diagnostic modality. 
 Shah A studied 262 thyroid lesions and found overall 
diagnostic accuracy for FNAC to be 84.66%, 97.13% for 
nonneoplastic and 80.45% for neoplastic lesions. He concluded that 
FNA is a useful tool in diagnosing thyroid lesions and to 
differentiate between nonneoplastic and neoplastic lesions 25. 
 Carpi et al advocated the use of scintiscanning and 
ultrasonography to be used along with Fine Needle Aspiration 
(FNA) 8. 
 Yang et al used of ultrafast papanicolaou stain in 
identifying nuclear abnormalities in papillary carcinomas of 
thyroid9.  
In 1989, Sharo Mair et al, performed both aspirational and non-
aspirational technique in 100 consecutive superficial mass in various 
body sites and concluded that non-aspirational technique produced 
superior quality material while aspirational technique produced adequate 
material.  
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Shukla PK(1993) used simple reusuable device from the barrel of 
10ml disposable plastic syringe to hold a piston of 20ml disposable 
syringe so as to produce continuous negative pressure. He found this 
method to be satisfactory and inexpensive. 
EMBRYOLOGY 
Thyroid is the first endocrine gland to appear in the embryo as 
early as 24 days of gestation. Thyroid gland developes as median 
endodermal down growth from the primitive pharynx in between 
first and second pharyngeal pouch. This median anlage form a 
hallow diverticulium that descends into the anterior neck which 
maintains its connection with the tongue by a narrow tube, the 
thyroglossal duct. 
The tip of the tubular duct bifurcates and divides the whole 
mass into a series of double cellular plates from where isthmus and 
lateral lobes of thyroid develops, which reaches the final position 
anterior to trachea at about seven weeks of gestation. The 
thyroglossal duct usually disappears at this stage, but the remnants 
of the duct may persist at any level during the course and later may 
develop as ectopic thyroid tissue and a median cyst. 
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The foramen caecum of the tongue represents the vestigial 
opening of the thyroglossal duct. The ultimobrachial body is derived 
from fourth and fifth pharyngeal pouch which fuses with the median 
thyroid anlage and becomes part of the lateral lobe of thyroid. The 
progenitors of “C” cells which are derived from the neural crest 
migrate to the ultimobrachial body before their incorporation into 
the developing thyroid gland. During fourteenth week the gland 
consists of well formed follicles lined by follicular epithelial cells 
and contains thyroglobulin positive colloid in the lumen. 
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ANATOMY: 
The normal adult thyroid gland weighs about 16-25gm. It is 
composed of right and left lobe connected by thin isthmus in midline. 
Each lobe has pointed superior pole and a blunt inferior pole26. There is a 
thin remnant of tract of decent at superior end of isthmus called as 
pyramidal lobe. 
Isthmus lies close to the ventral aspect of trachea covering 2 nd, 3rd 
and 4th tracheal rings. Each lobe is 5cm length and extends from the 
oblique line of the thyroid cartilage to 6 th tracheal ring. It is covered by 
pretracheal fascia which is firmly attached posteriorly to 2 nd, 3rd and 4th 
tracheal rings30,31,53. 
Arterial Supply : Thyroid gland is supplied by superior and 
inferior thyroid arteries which are the branches of external carotid 
arteries and thyrocervical trunk respectively 31. 
Venous Drainage :  Thyroid is drained by the superior, 
middle and inferior thyroid veins. Superior and middle thyroid veins 
drains into external jugular vein, while inferior thyroid vein drains 
into brachiocephalic vein31. 
Nerve Supply : Nerves to thyroid are mainly derived from 
cervical sympathetic ganglions.  These are vasoconstrictor. 
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Lymphatic Drainage :  Thyroid is drained by upper and lower 
deep cervical nodes. 
Upper part of the gland drains into upper deep cervical nodes 
either directly or through prelaryngeal nodes. Lower part of the 
gland drains into lower deep cervical nodes either directly or via 
pretracheal or paratracheal nodes31,53. 
The parafollicular cells are usually seen at the junction of 
upper 1/3rd and lower 2/3 rd of lateral lobes. They are the neural crest 
derivative and reaches thyroid via ultimobranchial body. 
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HISTOLOGY: 
The thyroid gland is enclosed by tense connective tissue 
capsule which extends into substance of the gland dividing into 
multiple lobules. Each lobule is made up of 20-40 follicules supplied 
by an end artery. 
 The functional and morphological unit of thyroid gland is 
follicles lined by single layer of follicular epithelial cells filled with 
colloid. The follicules vary in size with average diameter of 
200microns. The follicules are surrounded by rich network of 
capillaries, veins and lymphatics.  
According to the functional activity of the gland, the size and 
lining of the follicule, staining intensity of the colloid varies. In 
inactive gland, follicules are lined by flattened epithelial cells 
whereas in functional gland follicules are lined by tall cylindrical 
follicular epithelial cells.In hyperfunctioning gland colloid will be 
scant whereas it is dense, homogenous and intensly eosinophilic in 
hypoactive gland. 
The second minor component of the thyroid gland are 
represented by parafollicular “C” cells. With the standard technique 
the parafollicular cells are difficult or impossible to distinguish from 
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follicular epithelial cells without using special staining procedure. 
They are large polygonal or spindle shaped cells than follicleswith 
lightly granular nucleus and small indistinct nucleolus 30,31. 
Solid cell rests29 are remnants of ultimobrachial bodies which 
are usually found along central axis of the middle and upper third of 
the lateral lobes. They mainly composed of polygonal or oval cells 
admixed with occasional clear cells. 
Other structures that are found in the thyroid are parathyroid 
glands, normal thymus, salivary gland remnants, and occasional 
teratomatous elements like cartilage 28. 
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PHYSIOLOGY: 
 Thyroid secretes two hormones thyroxine(T3) and 
triiodothyronine(T4) which is controlled by thyroid stimulating 
factor(TSH) secreted by anterior pituitary gland, which in turn 
controlled by thyroid hormone releasing hormone(TRH) secreted by 
hypothalamus by classical negative feedback loop . It also secretes 
another hormone calcitonin which plays a major role in calcium 
metabolism30. 
  The steps involved in thyroid hormone synthesis are as 
follows: 
1. Iodide trapping – sodium iodide symporter transports 
iodide from blood to thyroid follicules 
2. Oxidation of iodidie ion – by the enzyme peroxidase 
3. Organification of thyroglobulin(TG) – Binding of iodine 
with tyrosine portion of TG 
4. Iodination of tyrosine and formation of thyroid 
hormones by coupling reaction. 
The iodotyrosine residues are condensed to form the 
biologically active thyroid hormones, T3,T4 which are stores as 
thyroglobulin in colloid. When the gland is stimulated,  there will be 
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endocytosis of colloid and proteolysis of thyroglobulin by lysosomal 
enzymes and release of T3&T4 into the circulation. 
After the hormones are secreted they are released into 
circulation, peripheral conversion of T4 to T3 occurs by 
deiodination. Triiodothyronine(T3) has high affinity and greater 
activity when compared to T427,30. 
Calcitonin, 32 aminoacid peptide secreted by parathyroid 
gland,mainly controls calcium metabolism in the body. 
Common clinical manifestations: 
Diseases of thyroid gland are grouped into three categories 
v Hyperthyroidism - excessive release of thyroid hormones. 
v Hypothyroidism – deficiency of thyroid hormones. 
v Mass lesions of thyroid32 
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HYPERTHYROIDISM: 
The common symptoms of increased secretions of thyroid 
hormone are 
v Weight loss. 
v Excessive appetite. 
v Heat intolerance. 
v Sweating. 
v Palpitations. 
v Tremors. 
v Emotional liability. 
v Tiredness. 
v Diarrhea. 
The signs of hyperthyroidism are 
v Tachycardia. 
v Hot moist palms. 
v Exophthalmos. 
v Eyelid retraction / lid lag. 
v Agitation. 
v Goiter. 
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HYPOTHYROIDISM: 
The common symptoms of decreased secretions of thyroid 
hormones are 
v Weight gain. 
v Constipation. 
v Cold intolerance. 
v Menstrual disturbances. 
v Lethargy. 
v Tiredness/weakness. 
v Hoarseness of voice. 
The signs of hypothyroidism are 
v Bradycardia. 
v Cold extremeties. 
v Dry skin and hair. 
v Periorbital puffines. 
v Hoarseness of voice. 
v Bradykinesis. 
v Delayed relaxation of ankle jerk. 
v Carpeltunnel syndrome24,31 
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CYTOLOGY: 
 The interpretation of cytological features depends on 
evaluation of cellularity, architectural pattern of tissue fragments in 
low power, cytological features in high power and background 
characteristics33. 
 A cytological sample is considered satisfactory when four to 
six clusters of follicular epithelial cells are seen in atleast two slides 
prepared from two needle passes10 
 The cytology of normal thyroid gland includes  
Ø Follicular epithelial cells. 
Ø Colloid. 
Ø Skeletal muscle. 
Ø Cartilage. 
Ø Tracheal epithelium. 
Follicular epithelial cells: 
 Follicular epithelial cells are dispersed or in small clusters. 
Some of the follicules are fragile, loses their cytoplasm and appear 
as bare nuclei similar to normal small lymphocyte. These follicules 
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are cuboidal cells with regularly spaced nuclei, pale cytoplasm 
arranged around lumen with or without colloid 34,35. 
Colloid: 
 Colloid has different staining character with different stains 
and fixation procedures. It stains pink with alcholol fixed H&E stain. 
They stain pale green to orange pink with cracking artefact and 
clumping in PAP stain. Colloid stain deep magenta in air dried 
Romanowsky stain36,35,22,34. Sometimes colloid may be washed away 
during processing, but parched earth or crazy pavement like artefact 
may be seen indicating the presence of colloid. 
The cytological features19,22 of individual thyroid lesions are 
described below: 
Thyroid cyst: 
 The fluid aspirated from a thyroid cyst usually contains numerous 
foamy macrophages, sometimes  haemosiderin laden (siderophages), 
altered blood, colloid and small clusters of benign thyroid epithelial cells. 
Papillary carcinoma thyroid also present as cystic lesion and the presence 
of psammoma bodies in the aspirated fluid should cause concern while 
reporting. 
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Thyroiditis:  
 Thyroiditis includes lymphocytic thyroiditis, Hashimoto 
thyroiditis, De Quervain's thyroiditis and Riedel’s thyroidits. Large 
number of lymphocytes and plasma cells are present in both lymphocytic 
and Hashimoto thyroiditis but presence of Hurthle cells, multinucleated 
giant cells and epitheloid histiocytes differentiates hashimoto thyroiditis 
from lymphocytic thyroiditis. Cytology of  De Quervain’s thyroiditis 
shows large multinucleated giant histiocytes, nuclear debris, 
inflammatory cells including neutrophils, lymphocytes and presence of 
abundant colloid. Usually there will be history of viral illness followed by 
thyroid enlargement in de quervain’s thyroiditis. 
Simple colloid goiter: 
 Smears usually show normal cytological appearance of follicular 
epithelial cells along with presence of abundant very thick colloid. 
Nodular goiter: 
 Smears in nodular goiter usually shows 
§ Abundant thick and thin colloid 
§ Follicular epithelial cells in monolayered sheets, 
poorly cohesive groups 
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§ Globular colloid masses superimposed with follicular 
epithelial cells 
§ Plenty of bare nuclei 
§ Large hyperplastic follicular epithelial cells with 
abundant vacuolated cytoplasm and fire flares 
§ Hurthle cells, pigment laden histiocytes and cell debris 
Follicular neoplasm: 
 Follicular adenoma and follicular carcinoma are distinguished only 
in histology with presence of capsular and vascular invasion. These two 
groups along with follicular variant of papillary carcinoma of thyroid 
comes under follicular neoplasm. 
 In FNAC, the follicular neoplasm includes 
§ Repetitive microfollicular pattern 
§ Rosettes, syncytial groups and equal sized follicular 
epithelial cell clusters  
§ Bloody and colloid free background 
Papillary carcinoma thyroid (PTC): 
 Smears are usually cellular with numerous papillary fragments and 
three dimensional clusters of follicular epithelial cells. Sometimes 
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papillae are removed intact but appear as flat sheets with distinct 
anatomical borders. PTC has distinct nuclear features which are well 
visualized in cytology. They are 
§ Nuclear crowding 
§ Nuclear overlapping 
§ Nuclear grooving 
§ Intranuclear inclusions 
§ Ovoid pale nuclei with fine granular powdery 
chromatin 
Scanty viscous chewing gum colloid is one of the striking feature 
in papillary carcinoma. The background shows macrophages, debris, 
multinucleated giant cells, lymphocytes and cystic degeneration. 
Medullary carcinoma: 
Smears are usually cellular with round, polygonal and spindle cells 
some are plasmacytoid cells with eccentric nucleus and moderate amount 
of cytoplasm and well defined cell margins. The nucleus show 
anisocytosis and fine stippled or coarsely granular cytoplasm. Sometimes 
amyloid may also be detected in the smear. 
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Anaplastic carcinoma: 
These are the most aggressive tumours of thyroid. Smears contains 
three major patterns or in combination of either giant cells, spindle cells 
and squamoid cells along with necrotic background with dissociated 
pleomorphic malignant cells and abnormal mitosis 
 Lymphomas can also occur in thyroid either as primary tumour or 
as part of systemic tumours. Presence of monotonous population of 
atypical malignant lymphocytes as on Non-Hodgkin’s lymphoma or Reed 
steinberg cells as in Hodgkin’s lymphoma favours diagnosis 
Metastatis to thyroid are usually rare. Breast, kidney, lung , 
gastrointestinal malignancies metastatis to thyroid. Smears are similar as 
their histology. 
Sometimes extraneous cells like muscle can be seen when 
needle is passed through muscle. 
 There are no absolute contraindication for Fine needle 
aspiration in thyroid lesions if patient is cooperative 36,22. 
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COMPLICATIONS: 
 There are certain rare complications that can occur during 
needle aspiration in thyroid. They are 
Ø Local hemorrhage due to needling and occasionally hematoma 
in anterior neck11,12 
Ø Airway compression. 
Ø Carotid hematoma13. 
Ø Transient vocal cord paralysis. 
Ø Acute transient goiter14 
Ø Acute suppurative thyroiditis15 
Ø Chemical neuritis16 
Ø Puncturing of trachea causes coughing. 
Ø Occasionally hemorrhage, necrosis or infarction obscure 
histological pattern of thyroid neoplasms. 
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TERMINOLOGY & REPORTING: 
There has been variety of terminology used for reporting 
thyroid FNA. They are 
1. The Papanicolaou Society task force17 on standards of practice 
in 1996 produced the following reporting scheme: 
v Inadequate. 
v Benign Nonneoplastic. 
o Colloid nodule. 
o Nodular goiter. 
o Cystic goiter. 
o Thyroiditis. 
v Cellular follicular lesion. 
o Favour hyperplastic (adenomatous) nodule. 
o Follicular neoplasm. 
v Hurthle cell neoplasm. 
v Malignant. 
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2. The most recent terminology has been given by National 
cancer Institute – sponsored Thyroid Fine Needle Aspiration 
State of the Science conference18 and the guidelines are: 
v Nondiagnostic(unsatisfactory). 
v Benign. 
o Colloid nodule. 
o Nodular goiter. 
o Hyperplastic (adenomatoid ) nodule. 
o Chronic lymphocytic thyroiditis. 
v Follicular lesion(atypia) of undetermined significance. 
v Neoplasm. 
o Follicular neoplasm. 
o Hurthle cell neoplasm. 
v Suspicious for malignancy. 
v Malignant. 
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3. The Bethesda system of reporting19 includes 6 categories. 
v Nondiagnostic. 
v Benign. 
v Atypia of undetermined origin. 
v FN/ Suspicious of FN. 
v Suspicious of malignancy. 
v Malignant. 
Principle lesions in thyroid aspiration cytology are (Koss GL) 37 
v Cysts. 
v Colloid goiter(adenomatous, nodular, diffuse). 
v Thyroiditis (acute, subacute, lymphocytic/ autoimmune). 
v Adenoma. 
v Carcinoma. 
o Papillary carcinoma and its variant. 
o Follicular neoplasms. 
o Medullary carcinoma. 
o Anaplastic carcinoma. 
§ Large cell. 
§ Small cell. 
v Malignant lymphoma. 
v Metastatic tumours. 
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WHO Classification of thyroid tumours: 
a) Tumours of thyroid follicular or metaplastic epithelium 
1. Follicular adenoma (including Hurthle cell adenoma) 
i. Follicular carcinoma (including Hurthle cell carcinoma) 
a. Minimally invasive. 
b. Widely invasive. 
ii. Papillary carcinoma. 
iii. Poorly differentiated thyroid carcinoma, including insular 
carcinoma. 
iv. Anaplastic (undifferentiated) and squamous cell carcinoma, 
including so-called carcinosarcoma. 
v. Columnar cell carcinoma. 
vi. Mucoepidermoid carcinoma. 
vii. Sclerosing mucoepidermoid carcinoma with eosinophilia. 
viii. Mucinous carcinoma. 
b) Tumours showing C-cell differentiation : 
 Medullary carcinoma. 
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c) Tumours showing both follicular and C-Cell 
 differentiation: 
i) Collision tumor: Follicular/papillary and medullary  
  carcinoma. 
ii) Mixed follicular: Parafollicular carcinoma   
  (differentiated thyroid carcinoma, intermediate type) 
d) Tumours showing thymus or related branchial pouch 
differentiation: 
i) Ectopic thymoma. 
ii) Spindle Epithelial tumour with thymus like element 
(SETTLE). 
iii) Carcinoma showing thymus like element (CASTLE) 
or intrathyroid thymic carcinoma. 
e) Tumours of lymphoid cells : 
i) Malignant lymphoma 
ii) Plasmacytoma 
f) Intrathyroid parathyroid tumour : 
i) Parathyroid adenoma. 
ii) Parathyroid carcinoma. 
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g) Mesenchymal and other tumours : 
i) Benign and malignant mesenchymal tumours, such as 
solitary fibrous tumours, smooth muscle tumour, peripheral 
nerve sheath tumour, angiosarcoma. 
ii) Paraganglioma. 
iii) Teratoma. 
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IMMUNOHISTOCHEMISTRY IN THYROID: 
Immunohistochemical analysis has been widely used in diagnosing 
many unequivocal thyroid tumours. Thyroid lesions with nodular 
architecture and follicular growth pattern often pose diagnostic difficulty 
during the assessment of cytologic and histologic specimens. The 
diagnosis of follicular neoplasm on cytology or follicular tumor of 
uncertain malignant potential on histology is likely to cause confusion 
and delay effective management of these lesions. Occasionally, thyroid 
tumors represent unusual or metastatic lesions and their accurate 
diagnosis required for proper management. 
 
 Most thyroid tumors can be readily diagnosed using 
histopathologic criteria, thereby allowing the pathologist to differentiate 
between benign and malignant lesions and to make an accurate 
classification for the majority of the variants of carcinomas derived from 
follicular epithelial cells. However, in most cases, this distinction 
becomes subtle. The decision favouring one or another has its clinical 
consequences and implies different modalities of treatment. At first, there 
should be a need to avoid excessive treatment and psychological 
discomfort to the patient. Secondly, patients with aggressive disease 
course need to have effective management at the initial stages when it is 
still curable. 
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 For this reason, the approach to these challenging tumors should 
include ancillary techniques, like immunohistochemistry and molecular 
profiling, which can improve the standard morphologic assessment both 
in cytological samples and surgical specimens28. 
 Several immunohistochemical markers using different 
antibodies, either alone or combined in panels, have been postulated to 
improve the diagnostic accuracy of thyroid lesions. 
 So, in this study we are using the two immunohistochemical 
markers namely 
 p53 
 Ki-67  
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p53 gene 
 
p53 (Tp53) protein was first identified in the year 1979 as a 
transformation- related protein39 and a cellular protein. These protein 
accumulates in the nuclei of cancer cells and binds tightly to the simian 
virus 40 (SV40) large T antigen40,41.  
 
  p53 is a nuclear phosphoprotein of MW 53 kDa, and encoded by a 
20-Kb gene containing 11 exons and 10 introns 41, which is located on the 
short arm of chromosome 1742. There are two other members in this 
family of genes, p63 and p73. 
 
Structure of p53: 
 Wild-type p53 protein contains 393 amino acids and is composed 
of several structural and functional domains. It has an N-terminus 
containing an amino-terminal domain and a proline-rich region, a central 
core domain and a C terminal region containing an oligomerization, a 
strongly basic carboxylterminal regulatory domain, a nuclear localization 
signal sequence and 3 nuclear export signal sequence 42. 
 The amino-terminal domain is required for transactivation activity 
and interacts with various transcription factors like acetyltransferases and 
MDM2 (murine double minute 2). The proline-rich region plays a vital 
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role in stability of p53 regulated by MDM2, where it becomes more 
susceptible to degradation by MDM2 if this region is deleted. 
 The central core of this protein is made up of DNA-binding 
domain required for sequence-specific DNA binding. The basic C-
terminus of p53 also functions as a negative regulatory domain and has a 
role in induction of cell death. C terminal tail of p53 regulates core DNA 
binding domain. If this interaction is disrupted by posttranslational 
modification, the DNA binding domain will become more active, thus 
inducing an enhanced transcriptional activity 43,44.  
 Most of the p53 mutations found in human cancers are missense 
mutation in central DNA binding domain. In p53 family of proteins both 
p63 and p73 show considerable homology with p53 but at the same time 
have structural and functional differences. 
Physiology of p53: 
 p53 is an important tumor suppressor gene, as it integrates with 
multiple stress signals and regulates cell response to DNA damage by the 
induction of  series of target genes, which regulate cell cycle arrest. This 
allows DNA damage repair or apoptosis of severely damaged cells. 
These biological effects are elicited by p53 binding to responsive 
promoters which, in turn, activate the transcription of several genes like 
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p21 (G1 cell growth arrest), Bax, and PUMA. Another major target gene 
of p53 is Mdm2, an ubiquitin ligase that binds to the N-terminus of the 
p53 protein and causes p53 inactivation, nuclear export and degradation. 
Mdm2 along with p53 acts as amajor negative feedback loop aimed at 
reducing 
p53 proapoptotic function and thus allowing cell repair. p53 is also 
a major regulator for cell senescence. Telomere shortening caused by cell 
replications triggers p53 activation, thereby blocking cell cycle and 
favours the cell entry into the stage of senescence.  
As a consequence, p53 inactivation or mutation may contribute to 
the increased number of cell replications and accumulation of genetic 
abnormalities in human cancers42,43,44,49 . 
Mutation of p53: 
 The p53 gene is often found to be genetically altered in most of the 
tumors, and is one of the frequently inactivated genes in the human 
cancers. Aberrant stimulation of cell proliferation leads to DNA 
replication stress, DNA double standard breaks, genomic instability, 
activation of the DNA damage checkpoint, and ultimately leads to p53-
dependent apoptosis.  p53 mutation is frequently seen in 70% of lung 
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cancer, 60% in colon, head and neck, ovary, and bladder and 45% in 
stomach cancer43,44,49.  
Because of the short half life of wild type p53, they remain 
undetectable when analysed by IHC, whereas mutated p53 can be readily 
detected by IHC in various malignancies because of its long half- life 69. 
 
 There are two forms of p53, wild (normal) type and mutated type. 
Wild type (wt) p53 are mainly responsible for series of biological 
consequences like cell cycle regulation, induction of apoptosis, 
development, differentiation, gene amplification and cellular 
senescence44. Hence p53 gene was known as “Guardian of genome”43. 
 
 Because of the short half life of wild type p53, they remain 
undetectable when analysed by IHC, whereas mutated p53 can be readily 
detected by IHC in various malignancies because of its long half- life 69. 
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p53 gene in thyroid: 
 
 Mutated p53 is seen in most of the human cancers45 accounting for 
50% of cases48, but they are expressed as late genetic event in thyroid 
neoplasms accounting for 10% of cases49,51,52. p53 is expressed mainly in 
anaplastic and poorly differentiated thyroid carcinomas 50 and rarely in 
well differentiated tumours like papillary and follicular carcinoma as well 
as in medullary carcinoma thyroid.  
 
 These observations suggests that p53  plays minor role in thyroid 
cancers where its mutation indicates tumour progression to 
aggressiveness or invasive subtypes. 
 
 Positive p53 immunoreactivity in thyroid neoplasms  acts as an 
independent prognostic factor for the survival of patients with thyroid 
cancer46,47. 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
  
49 
Ki-67 gene 
 
 Ki-67 gene was first described in the year 1983 by Gerdes et al91 
after immunising mice with Hodgkin’s lymphoma cell line L428. The 
antibody was named after its production in the city of Kiel (Hence Ki), 
Germany. 67 referes to the clone number on 96 well plates from which it 
was found. The Ki-67 gene was located on the long arm of chromosome 
10(10q25) with half life of 60-90mins.  
 
 Ki-67 antigen represents nuclear nonhistone protein which is 
expressed by the cells in proliferative phase53. The Ki-67 protein is a 
large (395 kD) nuclear protein that is expressed during all active phases 
of the cell cycle except in G0 phase indicating there is correlation 
between Ki-67 immunoreaction and mitotic activity55. Since proliferation 
status is closely associated with tumor aggressiveness, the Ki-67 labeling 
index (LI) is considered as an established prognostic marker for various 
tumor types54,56. 
 
The Ki-67 is a protein phosphorylated via serine and threonine 
with a critical role in cell division and expressed in mitotically active 
cells. 
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The expression of the Ki-67 protein as an indicator of proliferation 
marker requires two criteria. frist the antigen should be continuously 
present during all phases of cell cycle and secondly,the antigen should 
rapidly disappear in non proliferative phase ie Go phase. Although it has 
been reported that Ki-67 antigen show staining  faint or even 
undetectable at the onset of DNA synthesis it is generally accepted that 
the Ki-67 protein is expressed during all active phases of the cell cycle. 
Furthermore, all tissues tested showed positive Ki-67 staining in all 
proliferative phases of cell cycle67,91. 
Ki-67 expression correlates well with disease course and helps as a 
significant predictor for overall survival of the patients and presence of 
distant metastasis. The predictive value of  Ki-67 labelling index has 
been studied in breast and prostate cancers.  The prognostic value of the 
Ki-67 index is particularly important in those types of cancers in which 
the clinical course is difficult to predict based on histological criteria. Ki-
67 labelling index is an independent and significant prognostic factor for 
disease-specific survival of the patient.  Ki-67 labeling index also has a 
role in predicting how a tumor responds to a certain type of therapy 54,55. 
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Ki-67 in thyroid: 
 The Ki-67 labelling index will be lower in papillary carcinoma 
thyroid when compared to breast, colon or prostrate carcinoma. Ki-67 
proliferation activity has limited role in diagnosing thyroid neoplasm 
whereas this marker is mainly used to differentiate benign and malignant 
thyroid lesions.  
Follicular growth pattern pose a diagnostic difficulty wherein Ki-
67 labelling index helps in differentiating follicular adenoma from 
follicular variant carcinoma. Ki-67 expression is maximum in medullary 
carcinoma thyroid but low in well differentiated tumours like papillary 
and follicular carcinoma66,67,68. 
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IMMUNOHISTOCHEMISTRY 
 
 The two disciplines in immunohistochemistry are immunology and 
histology. 
 
 IHC is used to determine expression of antigen in tissues by using 
antibodies thereby aids in identifying lineage of cell population and 
define biologically distinct population of cells with same lineage. 
 
 Immunohistochemistry was first started by Coons and Jones 57 by 
using immunofluorescence technique in frozen sections. Later in 1966 
Pierce modified this procedure and used in paraffin sections. In 1991 Shi 
and his associates introduced antigen retrivel technique. In this method 
paraffin processed sections are heated at high temperature before IHC 
staining. Depending on the sensitivity and specificity of antigen- 
antibody reaction antibodies are used in IHC which is provided by 
Hybridoma technique. 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
  
53 
BLOCKING NON-SPECIFIC BACKGROUND STAINING: 
 Endogenous enzymes or non specific binding are responsible for 
background staining. Pre-incubating the sections with serum from same 
species minimizes nonspecific binding with primary antibody. 
 Peroxidise acts as endogenous enzymes which is seen both in 
normal and neoplastic tissues. These are abolished by peroxidise 
blocking or by using alternate systems such as immunogold technique. 
 Endogenous activity is overcomed by incubating the sections 
either in methanol containing 0.5% hydrogen peroxidise for about 10min 
at room temperature or by adding 0.1M concentration of levamisole to 
the enzyme substrate solution. 
 
DETECTION SYSTEMS: 
 
 For visualisation of antigens antibodies are labelled or flagged with 
fluorescent substances, enzymes forming coloured reaction with suitable 
substrate or by using heavy metals. Enzymes are most commonly used in 
IHC. Incubation with a chromogen produces a stable end product suitable 
for light microscopy. 
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METHODS OF IHC 
 
DIRECT LABELLING METHOD: 
 In this method antibody is attached with a label by chemical means 
and directly applied to tissue sections. The main advantage of this 
method is that it is rapid and easy procedure, but carries low sensitivity. 
 
INDIRECT LABELLING METHOD: 
 In this method enzymes are labelled with secondary antibodies 
which are produced against primary antibody. This technique is more 
sensitive and easy to handle.  
 
AVIDIN BIOTIN CONJUGATE METHOD: 
 In this method primary antibody is added followed by biotinylated 
secondary antibody and which in turn followed by preformed complexes 
of Avidin and Biotin horse radish peroxidise conjugate. This method is 
more specific but endogenous biotin produces background staining. 
 
BIOTIN STREPTAVIDIN METHOD: 
  Instead of avidin, streptavidin is used in this method. Streptavin are 
more stable and also reduces background staining. 
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IMMUNOGOLD WITH SILVER ENHANCEMENT: 
 This technique represents the most sensitive and effective light 
microscopic immunohistochemical method currently available. In this 
method the gold particles are enhanced by the addition of several layers 
of metallic silver. Tih method is also used in ultrastructural 
immunolocalisation. 
 
POLYMERIC METHOD: 
  In this method Dextran backbone are used for binding of large 
number of enzyme molecules to secondary antibody. This method 
increases sensitivity, minimizes non specific background staining and 
reduces total number of assay steps. 
 
IMMUNOHISTOCHEMISTRY PROCESS: 
 In IHC the tissue has to undergo following steps like fixation, 
dehydration and paraffin embedding as in routine H&E sections. 
 
FIXATION: 
 This is a critical step in interpretation of  IHC as it preserves the 
tissue morphology. 10% buffered formalin is a ideal fixative for IHC. 
The main disadvantage of this fixation technique is that it masks the 
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antigens within the tissues which is overcome by antigen retrieval 
technique. 
 
ANTIGEN RETRIEVAL: 
 This method involves unmasking of antigens. The following 
techniques can be used. 
 
v Proteolytic enzyme digestion 
v Microwave antigen retrieval 
v Pressure cooker antigen retrieval 
v Microwave and trypsin antigen retrieval 
 
 Pressure cooker antigen retrieval is most commonly used technique 
in IHC. Care should be taken to allow section to dry as this destroys 
antigenicity.  
 
CONTROLS: 
  Control tissue is essential in IHC. Use of internal control protects 
against the effect of poor fixation.  
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MATERIALS AND METHODS 
After obtaining ethical committee clearance in our college, 
Kilpauk Medical College, the study was conducted at the Department of 
Pathology. 
A total of 200 cases of thyroid lesons were included in study 
between the year June 2010 to June 2014 from three collaborative 
departments – Department of General surgery Kilpauk Medical College, 
Government Peripheral Hospital AnnaNagar and ESI Hospital 
Ayanavaram, Chennai. 
Study designs were both prospective and retrospective. For 
retrospective study the case notes were retrieved from the records and 
information about age, sex, clinical presentation, biochemical results, 
cytological and histological diagnosis were reviewed. For prospective 
study all these findings were directly obtained from patients after getting 
consent and then cytological and histological diagnosis was done. 
Immunohistochemical analysis was done in 50 cases using 
antibodies for Ki-67 and p53. In this study, various thyroid lesions like 
adenomatous goiter, toxic goiter, dominant nodule of nodular colloid 
goiter, hyperplastic nodule, colloid nodule/goiter are grouped under the 
spectrum of nodular goiter in cytology and histopathology. 
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CYTOLOGICAL STUDY: 
 After examining the patient, FNA was done by using 23-24 gauge 
needles with the patient in supine position and slight extension of neck to 
make the thyroid swelling more prominent. Without any negative 
pressure, aspiration was done by capillary suction, while instructing the 
patient to refrain from swallowing. Negative pressure was given in cases 
where colloid was aspirated. Aspirate was then expressed in a clean glass 
slide and smeared. At least three slides were made; all the slides were 
placed in 95% Isopropyl alcohol for 20mins for fixation and stained with 
Hematoxylin and Eosin stain. 
Steps of staining procedure:     
1. Harris hematoxylin – 5 mins. 
2. Running tap water- 2 dips. 
3. Decolourisation – 1% acid alcohol for 5-10 secs. 
4. Blueing – running tapwater for 10-15 mins. 
5. Counterstain – 1% aqueous eosin for 1-2 mins. 
6. Wash in water. 
7. Mounting with DPX. 
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Results:      
  Cytoplasm – Pink. 
   Nucleus – Blue. 
Histopathological Study: 
 All thyroidectomy specimens were received in 10% Buffered 
formalin and left for overnight fixation. Grossing of the specimens was 
done and representative samples/bits were taken and sent for routine 
tissue processing. 
Staining of Tissue Section: 
 Sections of about 4-5microns thick were cut from routinely 
processed paraffin embedded block and gently lowered on surface of 
water bath at 45 degree celsius to remove any folding. 
 Sections were then taken on alcohol cleaned glass slides smeared 
with thin film of egg albumin. 
 Slides were then warmed on a warmer at 58 degree Celsius for one 
hour, cooled and then stained. 
 Sections were then placed in two changes of Xylene for 2mins to 
remove the wax . 
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 Sections were placed in 2 changes of Absolute alcohol for 2mins to 
remove Xylene. 
 Sections were treated with descending grades of alcohol with 90% 
alcohol for 1min and 80% and 70% alcohol for 1min. 
 Finally, sections were brought to De ionised water and then stained 
by routine Hematoxylin and Eosin stain. 
 Cytological diagnosis was correlated with histopathology and 
efficacy of FNAC was estimated by using the methodology of Galen and 
Gambino as follows:58 
Sensitivity = TP/TP +FN x 100 
Specificity = TN/TN+FP x 100 
Efficacy = (TP+TN/TP+TN+FP+FN) x 100 
 TP = True Positive   TN = True Negative 
 FP = False Positive  FN = False Negative 
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These statistical values are interdependent statistical concepts 
showing accurate results. 
Thyroid FNA is useful for 
1. Detecting patients for thyroid malignancy (sensitivity). 
2. Excludes patients without malignancy (Specificity). 
3. Predicts the presence/absence of malignancy (positive & negative 
 predictive value). 
4. Classify patients who should have their nodules excised and who’s 
 excision is unnecessary (efficacy) 
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Immunohistochemistry 
 Immunohistochemistry was done in 50 cases. Paraffin blocks were 
chosen for IHC and stains used were p53 and Ki-67. 
 Sections were cut using the microtome with disposable blades. 
Slides are coated with chrom alum. Sections were subjected first to 
antigen retrieval using pressure cooker technique by citrate retrieval 
solution with pH 6. Then, sections are treated with Horse Radish 
Peroxidase (HRP) polymer technique for blocking endogenous antigens. 
Immunohistochemical stains: 
The following clones were used from Biogenex laboratories as 
immunohistochemical stains. 
v Clone DO 7 for p53 
v Clone v9 for Ki-67 
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Methodology: 
1. Chrom alum coated slides were taken through following stages. 
2. Treated with peroxidise block for inhibiting endogenous 
 peroxidase in tissue for 5mins. 
3. Washed two times in TRIS buffer for 5mins. 
4. Application of power block for about 5mins for blocking non-
 specific antigen antibody reaction. 
5. Washed two times in TRIS buffer for 5mins. 
6. Primary antibody was added to the section for 60mins. 
7. Wased two times in TRIS buffer for 5mins. 
8. Secondary antibody tagged with Horse Radish Peroxidase enzymes 
 were then added to the section for 30mins. 
9. Washed two times in TRIS buffer for 5mins. 
10. Super enhancer was applied to the section for 30mins mainly to 
enhance the final reaction product to increase the sensitivity of the 
antigen and antibody reaction. 
11. Washed two times in TRIS buffer for 5mins. 
12. DAB (Diamino benzidine) chromogen was then applied for 5mins. 
13. Washed in distilled water for 5mins. 
14. Counterstaining of the section was done by using hematoxylin. 
15. Air dried and mounted with DPX. 
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Results: 
 Both p53 and Ki-67 
 Positive – nuclear stain – Brown 
Methods of scoring for Ki-67 
All slides were evaluated. Cells with brown granular   nuclear 
staining were considered positive. An area with maximum proliferation 
was chosen to evaluate Ki-67 labelling index. A minimum of 1000 cells 
were counted in randomly selected areas. Labelling index was expressed 
as percentage of positively stained cells per 100 follicular epithelial cells. 
Score was given according to the intensity of the nuclear stain. 
 0 – < 2% of nuclear staining. 
 1 – 2% to 5% of nuclear staining. 
 2 – 6% to 10% of nuclear staining. 
 3 – > 10% of nuclear staining. 
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Methods of scoring for p53 
 Cells with nuclear staining were considered as positive. Score was 
given according to the intensity of the nuclear stain. 
 0 – No staining 
 1 – Weak staining 
 2 – Moderate staining 
 3 – Strong staining 
Percentage of positive cells70 
 0 – Negative staining 
 1 – The cells that is positive by less than 25% 
2 - The cells that is positive by 26-50%   
3 - The cells that are positive by >50%  
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Fig 1: Monolayered sheets and poorly cohesive clusters of  
follicular epithelial cells  and cyst macrophages –  
Nodular colloid Goiter. H&Ex10 
 
Fig 2: Cyst and Hemosiderin laden Macrophages in the  
background of thin colloid – Nodular colloid  
goiter with cystic degeneration. H&Ex10 
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Fig 3: Hurthle cells and Lymphocytes in the background of colloid – 
Hashimoto Thyroiditis. H&E x 10 
 
 
 
Fig 4: Hurthle cells – cells with abundant eosinophilic cytoplasm and 
anisocytosis of nucleus. H&E x10 
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Fig 5: Repetitive thyroid follicular epithelial cells with scant colloid– 
Follicular Neoplasm. H&E x 4 
 
Fig 6: Microfollicular pattern with  colloid–Follicular  
Neoplasm. H&E x 40 
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Fig 7: Sheats and Papillaroid fragments of Follicular epithelial cells – 
Papillary Carcinoma thyroid. H&E x 4 
 
Fig 8: Nuclear crowding, overlapping in Papillary Carcinoma thyroid. 
H&E x 10 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
  
70 
 
 
Fig 9: Nuclear Grooves and Intranuclear inclusions in Papillary 
Carcinoma Thyroid. H&E x 40 
 
 
 
Fig 10: Total thyroidectomy specimen C/S – single nodule measuring 3cm 
diameter filled with colloid – Nodular Colloid goiter 
 
551/14 
551/14 
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Fig 11: Total Thyroidectomy – C/S – greytan replacing entire thyroid 
parenchyma – Hashimoto thyroiditis 
 
 
 
Fig 12: Total Thyroidectomy specimen C/S-  shows a nodule measuring 
3x2cm with peripheral compressed normal thyroid parenchyma – 
Follicular Adenoma 
 
 
 
2705/13 
680/14 680/14 
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Fig 13: Total Thyroidectomy specimen C/S – Solid and cystic greywhite 
area – Papillary Carcinoma Thyroid 
 
Fig 14: Total Thyroidectomy specimen C/S- Cyst with mural nodule- 
Papillary carcinoma thyroid 
 
 
1567/13 
433/14 
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Fig 15: Follicles of varying sizes filled with colloid-Nodular colloid goiter. H&E x 
4 
 
Fig 16: Follicles lined by flattened epithelial cell with colloid- Nodular 
colloid goiter. H&E x 10 
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Fig 17: Hurthle cells with lymphocytes in the background - Hashimoto 
thyroiditis. H&E x 10 
 
Fig 18: Encapsulated lesion showing microfollicles of varying sizes -
Microfollicular adenoma.  H&E x 10 
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Fig 19: Uniform microfollicles lined by cuboidal follicular epithelial cells – 
Microfollicular adenoma. H&E x 40 
 
Fig 20: Circumscribed neoplasm showing Macrofollicles of varying sizes – 
Macrofollicular adenoma. H&E x 4 
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Fig 21: Macrofollicles lined by cuboidal epithelial cells with scant collid – 
Macrofollicular adenoma.  H&E x 10 
 
Fig 22: Nodular colloid goiter with foci of micropapillary carcinoma. H&E 
x 4 
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Fig 23:  Micropapillary carcinoma. H&E x 10 
 
Fig 24:  Encapsulated papillary carcinoma thyroid. H&E x 4 
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Fig 25: Follicular variant of  papillary carcinoma thyroid. H&E x 10 
 
Fig 26: Clear cell change in papillary carcinoma thyroid. H&E x 10 
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Fig 27: Papillae with prominent fibrovascular core in papillary carcinoma 
thyroid. H&E x 10 
 
 
Fig 28: Psammoma bodies and orphan annie eye nucleus in papillary 
carcinoma thyroid 
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Fig 29: Multinodular goiter showing 1% of  Ki-67 expression. x 40 
 
Fig 30: Hashimoto thyroiditis showing 2-5% of Ki- 67 expression. X 40 
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Fig 31: 6-10% of nuclear positivity of  Ki-67 expression in Follicular 
adenoma. x 40 
 
Fig 32: 2-5% Ki-67 expression in Follicular adenoma. x 40 
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Fig 33: Papillary carcinoma thyroid showing 2- 5% Ki-67 expression. x 40 
 
Fig 34:6-10%Ki-67expression in papillary carcinoma thyroid.x40 
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Fig 35: >10% expression of Ki-67 in Papillary carcinoma thyroid- x40 
 
Fig 36: 100% negative staining of p53 in Nodular colloid goiter and 
Hashimoto thyroiditis. x40 
 
 
 
 
 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
  
84 
 
 
Fig 37: Weak positivity(<25%) of p53 in Hashimoto throiditis. x 40 
 
Fig 38: Moderate staining(26-50%) of p53 in Follicular adenoma. x40 
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Fig 39: Strong nuclear positivity(>50%) of p53 in Hurthle cell adenoma. 
x40 
 
Fig 40: Moderate nuclear positivity(26-50%) of p53 in Papillary 
carcinoma thyroid. x40 
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Fig 41: Strong nuclear positivity(>50%) of p53 in Papillary carcinoma 
thyroid.  x40 
 
Fig 42: Strong Nuclear positivity(>50%) in Papillary carcinoma thyroid in 
background of  Hashimoto thyroiditis. x40 
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OBSERVATIONS AND RESULTS 
TABLE 1 
INCIDENCE OF THYROID LESIONS IN HEAD AND NECK 
Duration 
of Study 
Total No. 
of 
Specimens 
Total No of 
Cases in 
Head & Neck 
Total No of 
cases in 
Thyroid 
Total No of 
Thyroid 
Malignancies 
JUNE 
2010 to 
JUNE 
2014 
20937 1540 200 21 
 
The total numbers of specimens received during the period of June 
2010 to June 2014 were 20937. Out of the 20937 specimens 1540 
specimens were from Head and neck region, of which 200 cases were 
from thyroid and 21 were thyroid tumours. 
In our study, the incidence of thyroid lesions over period of four 
years was 0.1% and incidence of thyroid tumours among head and neck 
lesions was 1.36%.  
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CHART - 1 
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TABLE 2 
AGE DISTRIBUTION OF THYROID LESIONS 
 
Age Group        
(in years) No of Cases 
Percentage 
(%) 
0 – 9 0 0.00 
10 – 19 5 2.50 
20 – 29 45 22.50 
30 – 39 56 28.00 
40 – 49 53 26.50 
50 – 59 30 15.00 
60 – 69 8 4.00 
70 – 79 2 1.00 
80 – 89 1 0.50 
Total 200 100 
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 Table 2 and chart 2 shows the incidence of thyroid lesions in 
different age groups. In our study, the youngest person reported was 
10yrs and the eldest one was 84yrs. The maximum number of cases 
(28%) reported was between 30-39 yrs of age followed by 40-49yrs of 
age (26%). About 54.5% of cases were more than 30yrs with median age 
of presentation being 39yrs. 
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CHART 2 
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TABLE - 3 
GENDER DISTRIBUTION OF THYROID LESIONS 
 
Gender No of Cases Percentage (%) 
Male 18 9 
Female 182 91 
Total 200 100 
 
 In our study, the occurrence of thyroid lesions was more common 
in females when compared to males.  Among 200 specimens, 182 
specimens belonged to female patients and 18 specimens were from male 
patients, as evident from table 3 and chart 3. 
Thus the incidence of thyroid lesions was higher in females with 
91%. The observed male : female ratio is 1:10.1. 
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CHART 3 
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TABLE 4 
FNAC & BIOPSY CORRELATION 
 
FNAC Correlation 
Correlation 
Percentage 
Positive 125 74 
Negative 44 26 
Total 169 100 
  
  Table 4 and chart 4 indicates total number of cases correlated. Out 
of 200 cases, 31 cases FNAC was not done, remaining 169cases were 
taken into consideration for correlation. Out of 169 cases 125 cases 
(74%) were positively correlated and 44 cases (26%) were negatively 
correlated. 
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CHART 4 
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TABLE 5 
COMPARISON OF TYPE OF SPECIMEN RECEIVED 
 
Specimen Distribution No of Specimens Percentage (%) 
Sistrunk Operation 6 3.00 
Hemithyroidectomy 72 36.00 
Subtotal Thyroidectomy 28 14.00 
Neartotal Thyroidectomy 3 1.50 
Total Thyroidectomy 91 45.50 
Total 200 100 
 
 Among 200 thyroid specimens, total thyroidectomy  was  more 
common, constituting about 91 specimens(45%) followed by 
hemithyroidectomy constituting about 72  specimens(36%). 
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CHART 5 
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TABLE 6 
DISTRIBUTION OF NEOPLASTIC AND NON NEOPLASTIC 
LESIONS IN CYTOLOGY 
S.No Lesions No of Cases 
Percentage 
(%) 
1 Neoplastic 23 14 
2 Non Neoplastic 146 86 
 Total 169 100 
 
 In the present study, non neoplastic lesions were commonly 
encountered than neoplastic lesions. Out of 169 cases, non neoplastic 
were 146 cases (86%) and neoplastic were 23 cases (14%) with ratio of 
about 6.34:1. 
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CHART 6 
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TABLE 7 
DISTRIBUTION OF THYROID LESIONS BASED ON 
CYTOLOGY 
Thyroid Lesions Total no. of cases Incidence (%) 
Benign 16 9 
Inflammatory 12 7 
Malignant 7 4 
Non Neoplastic 134 79 
Total 169 100 
 
 In our study, non neoplastic lesions are more commonly 
encountered than neoplastic lesions. The lesions in present study were 
broadly classified into non neoplastic, benign, inflammatory and 
malignant.  Out of 169 cases, 134(79%) cases were non neoplastic, 16 
(9%) cases were benign, 12cases (7%) were inflammatory and 7(4%) 
were malignant. 
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CHART 7 
 
 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
  
102 
 
TABLE 8 
DISTRIBUTION OF INDIVIDUAL THYROID LESIONS BASED 
ON CYTOLOGY 
Diagnosis No of cases Incidence (%) 
Hashimoto Thyroiditis 12 7 
Thyroglossal Cyst 5 3 
Nodular Goiter 129 76 
Follicular Neoplasm 16 9 
Papillary Carcinoma 
Thyroid(PTC) 7 4 
Total 169 100 
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As shown in the Table 8 and chart 8, nodular goiter was the 
commonly encountered thyroid lesion. Out of 169 cases, 129(76%) cases 
were nodular goiter, 12 cases (7%) were Hashimoto thyroiditis, 16(9%) 
cases were follicular neoplasm, 7(4%) cases were papillary carcinoma 
thyroid (PTC) and 5(3%) cases were thyroglossal cyst. 
 Out of 169 cases, the most common non neoplastic lesion was 
nodular goiter (76%) followed by Hashimoto thyroiditis (7%) and most 
common neoplastic lesion was Follicular neoplasm(9%) followed by 
Papillary Carcinoma thyroid(4%). 
The various lesions like cystic lesion of thyroid, colloid nodule, 
adenomatous goiter, toxic goiter, dominant nodule of nodular colloid 
goiter, hyperplastic nodule are grouped under the spectrum of nodular 
colloid goiter.  
Lymphocytic thyroiditis and thyroiditis are grouped under 
hashimoto thyroiditis. 
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CHART 8 
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TABLE 9 
DISTRIBUTION OF THYROID LESIONS BASED ON 
HISTOPATHOLOGY 
Thyroid lesions HPE Frequency (%) 
Benign 46 
Inflammatory 20 
Malignant 21 
Non Neoplastic 113 
Total 200 
 
 Table 9 and chart 9 denotes distribution of lesions in total number 
of biopsy specimens received. Out of 200 cases, non neoplastic was more 
common constituting about 113(57%) specimens followed by benign 
cases(23%), malignant(10%) and inflammatory(10%) cases. 
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CHART 9 
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TABLE 10 
DISTRIBUTION OF INDIVIDUAL THYROID LESIONS BASED 
ON HISTOPATHOLOGY 
Diagnosis No of Cases Incidence (%) 
Hashimoto Thyroiditis 17 10 
Thyroglossal Cyst 5 3 
Nodular Goiter 103 61 
Follicular Adenoma 22 13 
Hurthle Cell Adenoma 1 1 
Hyalinising Trabecular 
Adenoma 1 1 
Papillary Carcinoma 
Thyroid(PTC) 20 12 
Total 169 100 
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  Table 10 and chart 10, denotes individual case distribution in 
histopathology which has correlated with cytology. Out of 169 cases, 
nodular goiter (61%) was more common followed by follicular 
adenoma(13%),  PTC(12%),  Hashimoto thyroiditis(10%), thyroglossal 
cyst(3%) and hurthie cell adenoma(1%) and  hyalinising trabecular 
adenoma(1%). 
The lesions like multinodular goiter, adenomatous goiter, nodular 
goiter with micropapillary hyperplacia are grouped under spectrum of 
nodular goiter. Some of the variants reported in papillary carcinoma of 
thyroid are micropapillary variant and encapsulated variant.  
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CHART 10 
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TABLE 11 
AGE WISE DISTRIBUTION OF INDIVIDUAL THYROID 
LESIONS 
 
Age 
Hashimoto 
Thyroiditis 
Thyroglossal 
Cyst 
Nodular 
Goiter 
Follicular 
Adenoma 
Papillary 
Carcinoma Total 
0 - 9 - - - - - 0 
10 - 19 1 - 2 1 1 5 
20 - 29 5 3 22 8 3 41 
30 - 39 5 2 35 9 8 59 
40 - 49 8 - 36 4 7 55 
50 - 59 2 1 22 3 1 29 
60 - 69 - - 5 2 1 8 
70 - 79 - - 2 - - 2 
80 - 89 - - - - 1 1 
Total Sample Size 200 
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Table 11 shows that the most affected age group in nodular goiter 
is 40 – 49 years. Out of 55 total cases in this category 36 cases (65%) 
were diagnosed for nodular goiter. Also the most affected age group in 
follicular adenoma and papillary carcinoma thyroid is 30 – 39 years. Out 
of 59 cases 9 cases(15%) belongs to follicular adenoma and 8 Cases 
(14%) belongs to papillary carcinoma. 
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TABLE 12 
AGE & SEX WISE DISTRIBUTION OF INDIVIDUAL THYROID 
LESIONS 
 
Age  
Hashimoto 
Thyroiditis 
Thyroglossal 
Cyst 
Nodular 
Goiter 
Follicular 
Adenoma 
Papillary 
Carcinoma Total 
  M F M F M F M F M F   
0 - 9 - - - - - - - - - - 0 
10 - 19 - 1 - - - 2 1 - - 1 5 
20 - 29 - 5 1 2 - 22 2 6 1 2 41 
30 - 39 - 5 - 2 1 34 - 9 2 6 59 
40 - 49 - 8 - - 3 33 - 4 - 7 55 
50 - 59 - 2 - 1 3 19 1 2 - 1 29 
60 - 69 - - - - 2 3 - 2 - 1 8 
70 - 79 - - - - 1 1 - - - - 2 
80 - 89 - - - - - - - - - 1 1 
Total Sample size   200 
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In the study females are more commonly affected than males. 
Among females nodular goiter are more common followed by follicular 
adenoma and papillary carcinoma thyroid. 
In 10 -19 yrs of age category, 2 cases out of 5 cases (40%) are 
diagnosed for nodular goiter in female. 
In 20 – 29 yrs of age category, 22 cases out of 41 cases (54%) are 
diagnosed for nodular goiter in female. 
In 30 – 39 yrs of age category, 34 cases out of 59 cases (58%) are 
diagnosed for nodular goiter in female. 
In 40 – 49 yrs of age category, 33 cases out of 55 cases (60%) are 
diagnosed for nodular goiter in female. 
In 50 – 59 yrs of age category, 19 cases out of 29 cases (66%) are 
diagnosed for nodular goiter in female. 
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TABLE 13 
CYTOHISTOPATHOLOGICAL CORRELATION OF THYROID 
LESIONS 
HPE   
TEST Benign Inflammatory Malignant 
Non 
Neoplastic Total 
Benign 12 0 1 3 16 
FNAC Inflammatory 0 10 0 2 12 
Malignant 0 0 7 0 7 
Non 
Neoplastic 29 6 11 88 134 
Total 41 16 19 93 169 
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Table 13 shows distribution of cases in histopathology followed by 
cytological aspiration. Out of 16 cases which was reported as benign in 
cytology, 12(75%) cases turned out to be benign, 1(6.25%) case reported 
to be malignant and 3(18.75%) cases turned out to be non neoplastic. Out 
of 12 cases reported as inflammatory in cytology, 10(83.33%) correlated 
with histopathology, 2(16.66%) cases turned out to be non neoplastic.  
All cases which were reported as malignant(100%) in cytology 
correlated well with histopathology. Out of  134 cases reported as non 
neoplastic in cytology, 29(21.64%) cases were benign, 6(4.47%) cases  
inflammatory, 11(8.20%) cases  malignant and 88(65.67%) cases non 
neoplastic  in histopathology. 
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TABLE 14 
CYTOHISTOPATHOLOGICAL CORRELATION OF 
INDIVIDUAL THYROID LESIONS 
FNAC SPECIFIC 
Test 
Follicular 
Neoplasm 
Hashimoto 
thyroiditis 
Nodular 
colloide 
goiter 
Papillary 
Carcinoma 
Thyroid 
Thyro 
glossal 
Cyst 
Total 
Follicular 
Adenoma 5 0 17 0 0 
22 
Hashimoto 
thyroiditis 0 10 7 0 0 
17 
Hurthle cell 
adenoma 0 0 1 0 0 
1 
HPE 
SPECIFIC 
Hyalinising 
trabecular 
adenoma 1 0 0 0 0 
1 
Nodular 
colloid 
goiter 8 2 92 0 1 
103 
Papillary 
Carcinoma 
Thyroid 1 0 12 7 0 
20 
Thyroglossal 
Cyst 0 0 1 0 4 
5 
Total 15 12 130 7 5 
169 
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  Table 14  indicates individual case distribution in cytology and its 
correlation in histopathology. Out of 15 cases of follicular neoplasm, 5 
cases (33.33%) were follicular adenoma, 1(6.66%) case HTA, 8 cases 
(53.33%)  nodular colloid goiter and 1 case (6.66%) PTC.  
 Out of 12 cases in Hashimoto thyroiditis in cytology, 2 (16.66%) 
cases turned out to be nodular colloid goiter. Out of 130 cases of nodular 
colloid goiter, 17 (13.07%) cases were Follicular Adenoma, 12 (9.23%) 
cases were PTC,7 (5.38%) were Hashimoto thyroiditis and 1(0.76%) case 
Hurthle cell Adenoma. Out of 5 cases reported as thyroglossal cyst, 
1(20%) case turned out to be nodular colloid goiter. 
 Significant agreement was observed between FNAC and 
histopathology as indicated by kappa(0.41) 
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TABLE  15 
CYTOHISTOPATHOLOGICAL CORRELATION OF 
PAPILLARY CARCINOMA THYROID 
PTC 
FNAC 
Positive Negative Total 
HPE 
Positive 7 13 20 
Negative 0 149 149 
Total 7 162 169 
 
 Table 15 denotes the sensitivity and specificity of  FNAC in 
Papillary Carcinoma Thyroid.  In our study, FNAC is 100% sensitive, 
91.98% specific for diagnosins Papillary carcinoma thyroid with 
accuracy of 92.31%.  
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TABLE 16 
CYTOHISTOPATHOLOGICAL CORRELATION OF 
FOLLICULAR NEOPLASM 
Follicular neoplasm 
FNAC 
Positive Negative Total 
HPE Positive 5 17 22 
Negative 10 137 147 
Total 15 154 169 
 
 In our study, FNAC is 33% sensitive,88.96% specific in 
diagnosing follicular adenoma with accuracy of 84.02%. 
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TABLE 17 
CYTOHISTOPATHOLOGICAL CORRELATION OF NODULAR 
COLLOID GOITER 
Nodular colloid goiter 
FNAC 
Positive Negative Total 
HPE 
Positive 92 11 103 
Negative 38 28 66 
Total 130 39 169 
 
 In our study, FNAC was 71% sensitive, 71.79% specific in 
diagnosing Nodular Colloid Goiter with accuracy of 71.01%. 
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TABLE 18 
CYTOHISTOPATHOLOGICAL CORRELATION OF 
HASHIMOTO THYROIDITIS 
Hashimoto thyroiditis 
FNAC 
Positive Negative Total 
HPE 
Positive 10 7 17 
Negative 2 150 152 
Total 12 157 169 
 
 In our study FNAC is 83% sensitive, 95.54% specific in 
diagnosing Hashimoto thyroiditis with diagnostic accuracy of about  
94.67%. 
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TABLE 19 
IMMUNOHISTOCHEMICAL EXPRESSION OF Ki-67 IN 
THYROID LESIONS 
LESIONS 
 0  
< 2 % 
1  
3% - 5% 
2  
6% - 10% 
3  
> 10% 
Total 
Cases 
Papillary 
Carcinoma 
Thyroid 1 5 11 4 21 
Follicular 
Adenoma 11 2 3 0 16 
Hurthle Cell 
Adenoma 0 2 0 0 2 
Hyalinising 
Trabecular 
Adenoma 0 0 1 0 1 
Nodular Goiter 5 1 2 0 8 
Hashimoto 
Thyroiditis 1 1 0 0 2 
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 Out of 21 cases in PTC, Ki-67 expression was maximum in 6-10%. 
Out of 16 cases of follicular adenoma, Ki-67 expression was maximum in 
< 2%. Out of 8 cases in nodular goiter 6 cases(75%) were below  < 5%. 
 Significant difference was observed between neoplastic and 
benign/non neoplastic thyroid lesions(P < 0.005) 
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TABLE 20 
IMMUNOHISTOCHEMICAL EXPRESSION OF p53 IN 
THYROID LESIONS 
 
LESIONS 0 1 2 3 
Total 
Cases 
Papillary Carcinoma 
Thyroid 1 10 8 2 21 
Follicular Adenoma 1 12 3 0 16 
Hurthle Cell Adenoma 0 1 1 0 2 
Hyalinising Trabecular 
Adenoma 0 0 1 0 1 
Nodular Goiter 2 4 2 0 8 
Hashimoto Thyroiditis 1 1 0 0 2 
 
 Out of  21 cases of PTC, p53 expression was maximum in grade 1 
followed by grade 2. Out of 16 cases of follicular adenoma p53 
expression was in grade 1 as with papillary carcinoma thyroid. 
 Statistically significant difference was observed between 
neoplastic and benign/ non neoplastic thyroid lesions (P 0.001) 
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DISCUSSION 
Thyroid enlargement, either diffuse or nodular leads to array of 
investigations mainly to rule out a neoplasm or thyroiditis. The main aim 
of cytological or histopathological examination is to guides the clinicians 
for appropriate management of patients. FNAC, as first line of 
investigation aids for the categorical management, followed by other 
modes of investigations like Ultrasonography, thyroid scan, TFT and 
level of antibodies. 
After obtaining ethical committee clearance, the study was 
conducted in the department of pathology at Kilpauk Medical College 
and hospital. A total of 200 specimens of thyroid have been received over 
the period from June 2010 to June 2014 which were analysed for 
cytohistopathological and immunohistochemical studies. 
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INCIDENCE 
 Carcinoma of the thyroid is rather uncommon with wide 
geographical variation in its incidence. In the UK, the annual incidence 
of thyroid malignancy is about between 2-3/100,000 population 60. In 
USA an average of 11000 cases of thyroid malignancy are reported every 
year and more than 1 person die each year61. In India thyroid malignancy 
constitute about 1% of all Head and Neck cancers. 
 In our study the incidence of thyroid cancers among Head and 
neck lesions is about 1.36% which is in concordance with the other 
studies. The incidence of papillary carcinoma thyroid is 10.50%. 
INCIDENCE OF CARCINOMA 
Study Year Percentage (%) 
Wagana et al 2002 16.00 
Rehman et al 2009 11.47 
Suresh et al  2012 10.60 
Present Study 2014 10.50 
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AGE 
In the previous studies by Quari86 et al and Talepoor84 et al in 
2005,  the mean age at presentation was 36.7yrs and 38.6yrs respectively. 
Khurshid Anwar in 2012 reported mean age at presentation as 37yrs. In 
the present study the mean age at presentation is found to be 39yrs with 
the range between 10 yrs and 84yrs which correlates with other studies. 
The median age of presentation for PTC in our study is 39yrs.  Most of 
the studies correlated with our study having the average age at initial 
diagnosis between 30-49yrs. 
Mean Age at Presentation 
AUTHORS MEAN AGE IN YEARS 
Cheung et al90 (2007) 46 
Khurshid Anwar et al89 (2012) 37 
Rajesh S et al82 (2013) 32.5 
Suresh et al (2013) 37.24 
Present Study 39 
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SEX DISTRIBUTION 
 In the previous studies done by Dorairajan et al(1996), Rajesh et 
al(2013) and Suresh(2013) the sex ratio was 1:9, 1:5 and 1:8.16 
respectively, which correlates with our present study with ratio of 1:10.1. 
AUTHORS SEX RATIO (M:F) 
Gupta et al85 (2001) 1:5 
Rajesh S et al82 (2013) 1:5 
Suresh et al (2013) 1:8.6 
Dorai Rajan et al83 (1996) 1:9 
Raafat A et al21 (2013) 7:10 
Present Study 1:10.1 
 
 Because of fluctuations in hormonal status in females as in 
puberty, menstrual cycle, pregnancy, menopause, the chances of 
formation of thyroid nodule in females are high when compared to males. 
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FNAC AS DIAGNOSTIC TOOL 
 Percentage of failure in making cytological diagnosis is not an 
uncommon feature. Present study shows failure rate of around 26% of 
cases. It makes distinct difference for surgeons to approach different 
investigation modalities for appropriate management. Present study was 
compared with previous studies conducted by various authors shown in 
table: 
Comparison of Value of FNAC as Diagnostic Tool 
Study (Year) No of Study Cases 
Positive 
Correlation 
(%) 
Kessler et al79 (2005) 170 80% 
Gupta et al80 (2006) 75 84% 
P Pandey et al81 (2012) 112 81% 
Rajesh et al82 (2013) 142 89% 
Present Study 169 74% 
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 In our study total of 74% cases in cytology have shown positive 
correlation in histopathology which correlates well with other studies. 
  26% of cases show negative correlation. The probable reasons for 
this negative correlation are  
Ø Faulty biopsy technique – too much or too little suction while 
 aspiration 
Ø Sampling error – biopsy needle in the tissue surrounding the 
 nodule 
Ø Long standing cysts with calcification – inadequate material 
Ø Thick fibrous calcified capsule 
Ø Highly vascular and sclerotic lesions 
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DISTRIBUTION OF THYROID LESIONS IN CYTOLOGY 
 In our study, non neoplastic lesions were common in cytological 
diagnosis when compared to neoplastic lesions which includes adenomas 
and malignancies. The ratio of non neoplastic lesions to neoplastic 
lesions is 6.34:1 is same when compared to other studies shown in table 
below 
Distribution of Non Neoplastic & Neoplastic Lesions Diagnosed by 
FNAC 
Authors 
Non 
Neoplastic Neoplastic Ratio 
Talepoor M et al84 (2005) 325 70 4.33:1 
Naggada et al88 (2006) 51 18 2.83:1 
Chao CT et al87 (2007) 276 264 1.04:1 
Suresh et al (2013) 36 19 1.89:1 
Present Study 146 23 6.34:1 
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CYTOHISTOPATHOLOGICAL CORRELATION 
 Sensitivity of thyroid FNAC varies from 78-92% and specificity 
varies from 74-99%62,63,64. In our study, the sensitivity in detecting 
neoplastic lesion is 82%, specificity 78% which is similar to other studies 
shown in table. Sensitivity for detecting Papillary carcinoma thyroid in 
our study is 100%, with specificity of 91.98% and diagnostic accuracy of 
about 92.31%. This shows FNAC is more sensitive in diagnosing thyroid 
malignancy. The diagnostic accuracy for detecting neoplastic lesions and 
papillary carcinoma thyroid are 97% and 92.31% respectively which 
correlates well with other studies. 
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Comparison with previous studies 
Authors 
Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
Bagga & Mahajan76 
(2010) 66 100 96.2 
Likhar et al77 (2013) 100 70 77.78 
Sarma Usha78 (2014) 95 95 92 
Present Study 100 91.98 92.31 
 
IMMUNOHISTOCHEMISTRY 
   Various studies have been published on immunohistochemical 
expression of Ki-67 and p53 in thyroid lesions to till date. Most of the 
studies conclude that Ki-67 and p53 can act as useful marker for 
differentiating benign and malignant thyroid lesions. 
Ki-67 in thyroid: 
 In our study, Ki-67 labelling index of 6-10% was observed 
maximally in papillary carcinoma thyroid in 52.38% of cases whereas 
follicular adenoma and nodular goiter show low proliferative activity of < 
2%. These findings are in close agreement with Erichson et al65. However 
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in present study there is significant difference in mean values between 
benign/non neoplastic and malignant lesions, but cut-off value for 
differentiating these cannot be given due to small sample size. Kjellman 
et al66 in his study suggested a cut off value of 1.9% or more for 
differentiating benign and malignant thyroid lesions. This is in 
concordant with our study as both benign and non neoplastic cases 
express < 2%. 
 The mean and range of Ki-67 labelling index for papillary 
carcinoma thyroid in our study are 9.33 and 1.63-17.03 respectively and 
for benign/non neoplastic lesions are 4.66 and 4.28-13.6. This 
observation is concordant with other studies of Singh et al 59, Yoshida et 
al71 and Basolo et al72, but in contrast to the study conducted by Wallin et 
al67 were the observed Ki-67 LI was 0.1-1% in non neoplastic lesions, 
0.3-1% in benign and 0.2-3.9% in malignant lesions.   
Out of 6 cases in nodular goiter, one case has micropapillary 
hyperplasia area which shows strong positivity in Ki-67 LI when 
compared to other cases. Hashimoto thyroiditis and nodular goiter shows 
weak positivity with Ki-67 LI, but some areas shows increased staining 
due to presence of lymphocytes which normally show nuclear positivity 
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p53 in thyroid 
 In studies related to p53 antibody in thyroid lesions, the p53 
expression was generally negative in well differentiated tumors, but 
strongly positive in anaplastic carcinomas 70. Donghi et al75 and Fagin et 
al50 in their studies reported that p53 mutation is seen 5 out of 7 
undifferentiated carcinomas and 5 out of 6 ATCs respectively. In present 
study all the malignant cases reported are papillary carcinoma thyroid. 
The positive staining was achieved in 48% of papillary carcinoma, 75% 
of follicular adenoma and 50% of nodular goiter. 
 In the present study all 21 malignant cases reported was Papillary 
carcinoma thyroid with p53 expression seen maximally in grade 
1(<25%). This low positivity of p53 expression in thyroid tumours may 
probably be due to lack of undifferentiated tumours in present study.  It 
has been proposed in other studies that p53 detection in 
immunohistochemistry may rarely be positive in early tumours and 
appear only as a late event. Our observations are in agreement with 
previous studies of Pollina et al73 and Okayasu et al74. 
 Out of 21 cases in papillary carcinoma thyroid, one case show no 
staining at all, this may be due to defective processing. There are also 
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variation in intensity of staining among malignant cases which is due to 
loss of heterogenecity of tumour and defective antigen retrieval. 
LIMITATIONS OF THE STUDY 
 Because of small sample size, lack of undifferentiated tumours and 
limited number of cases in benign and malignant cases in the study, a 
definite cut-off value for differentiating these thyroid lesions could not be 
ascertained. Larger sample sizes are needed to confirm this observation.  
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SUMMARY AND CONCLUSION 
Thyroid lesions are common in surgical practice with incidence of 
4-7% of the population82. The incidence of thyroid malignancy is 1% 
with papillary carcinoma of thyroid being the most common comprising 
about 84% of thyroid malignancies. 
The salient features observed in the study were: 
1. Thyroid lesions constitute about 12.98% of head and neck lesions.  
2. Thyroid tumours constitute about 1.36% of head & neck lesions. 
3. The incidence of papillary carcinoma of thyroid is 10.5% 
4. The common age group affected was 30-39yrs. 
5. The median age of presentation of papillary carcinoma thyroid was 
 39yrs. 
6. Females were commonly affected with male female ratio of about 
 1:10.1. 
7. 74% of thyroid FNAC had positive correlation with histopathology 
8. Non neoplastic lesions were more common than neoplastic lesions 
 in thyroid with a incidence of 86% 
9. Nodular goiter was more common among non neoplastic lesions in 
both cytology and histopathology with a incidence of 76% and 
61% respectively. 
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10.  Follicular adenoma was the most common neoplastic lesion in 
both cytology and histopathology with a incidence of 9% and 13% 
respectively. 
11. The sensitivity, specificity and diagnostic accuracy of FNAC in 
detecting neoplastic and non neoplastic lesions was 82%, 78% and 
97% respectively. 
12. The sensitivity, specificity and accuracy of FNAC for detecting 
papillary carcinoma of thyroid was 100%,91.98% and 92.31% 
13. Ki-67 staining was seen in 52.38% in PTC, 68.75% in follicular 
adenoma, 62.5% in nodular goiter 
14. p53 staining was seen in 47.62% in PTC, 75% in follicular 
adenoma and 50% in nodular goiter. Both these markers were 
statistically significant in differentiating non neoplastic and 
neoplastic lesions. 
 
In conclusion, FNAC is a safe, simple, rapid, cost effective and 
accurate method in diagnosing thyroid lesions with high sensitivity, 
specificity and efficacy. It can be used as an initial investigation in the 
management of thyroid diseases and avoid unnecessary surgery. 
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Most of the thyroid neoplasms are diagnosed based on their well 
characterised histological features. However there are certain subsets of 
tumours with follicular architecture that lack equivocal features of 
malignancy, thus posing diagnostic difficulty. In such cases, the use of 
ancillary techniques like Immunohistochemistry and molecular analysis 
can significantly improve the accuracy of diagnosis. 
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PROFORMA 
 
NAME: 
 
AGE: 
 
SEX: 
 
PERSONAL H/O: 
 
PAST H/O: 
 
H/O IRRADIATION: 
 
CLINICAL HISTORY: 
 
FNAC: 
 
HPE: 
 
DIAGNOSIS: 
 
IHC PANEL: 
 
CONCLUSION: 
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Thyrogloss
al Cyst 
Sistrunk 
Operation 
F442
/11 
Colloid 
Nodule 
639/1
1 
Thyroglossal 
Cyst           
28 Singari 
41
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F435
/11 
Colloid 
Nodule 
748/1
1 
Papillary 
Carcinoma 
Thyroid 
10
% 
30
% 
3
5
% 
3
0
% 
5
% 
29 
Dhanala
kshmi 
25
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy - - 
846/1
1 
Nodular 
Colloid goitre           
30 Revathy 
25
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F126
5/10 
Colloid 
Nodule 
892/1
1 
Multinodular 
goitre           
31 
Kannam
mal 
38
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F562
/11 Nodular Goitre 
902/1
1 
Nodular 
Colloid goitre           
32 Chitra 
40
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F676
/11 Nodular Goitre  
919/1
1 
Multinodular 
goitre           
33 
Kanchan
a 
36
/F 
Solitary 
thyroid 
Nodule 
Subtotal 
Thyroidectom
y 
F626
/11 Nodular Goitre 
953/1
1 
Multinodular 
goitre           
34 Amutha 
37
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F760
/11 Nodular Goitre 
993/1
1 
Multinodular 
goitre           
35 Devi 
28
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F714
/11 Nodular Goitre 
995/1
1 
Multinodular 
goitre           
36 Geetha 
37
/F 
Nodular 
Goitre 
Total 
Thyroidectom
y 
F384
/11 
Infected 
Thyroglossal 
cyst 
1034/
11 
Multinodular 
goitre           
37 Rajam 
45
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy - - 
1064/
11 
Multinodular 
goitre           
38 Amul 38 Solitary Hemithyroide F412 Nodular 1103/ Multinodular           
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/F thyroid 
Nodule 
ctomy /11 Colloid Goitre 11 goitre 
39 
Ramalak
shmi 
24
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F802
/11 Nodular Goitre 
1107/
11 
Adenomatous 
Goitre           
40 
Saraswa
thi 
41
/F 
Solitary 
thyroid 
Nodule 
Total 
Thyroidectom
y - - 
1140/
11 
Papillary 
Carcinoma 
Thyroid 
10
% 
50
% 
2
0
% 
2
0
% 
1
0
% 
41 
Meenak
shi 
25
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F858
/11 Nodular Goitre 
1147/
11 
Adenomatous 
Goitre           
42 Ramu 
40
/M 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F851
/11 Nodular Goitre 
1175/
11 
Adenomatous 
Goitre           
43 Vijayan 
58
/M 
Solitary 
thyroid 
Nodule 
Neartotal 
Thyroidectom
y 
F667
/11 
Follicular 
Neoplasm 
1184/
11 
Follicular 
Adenoma           
44 Kannagi 
24
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy - - 
1245/
11 
Hurthle cell 
adenoma 
4
% 
30
% 
2
0
% 
2
0
% 
2
0
% 
45 Nalini 
53
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F828
/11 
Nodular 
Colloid Goitre 
1260/
11 
Multinodular 
goitre           
46 Ammu 
28
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F903
/11 
Nodular 
Colloid Goitre 
1261/
11 
Adenomatous 
Goitre           
47 
Sambora
nam 
29
/F 
Thyrogloss
al Cyst 
Sistrunk 
Operation 
F801
/11 
Infected 
Thyroglossal 
cyst 
1289/
11 
Thyroglossal 
Cyst           
48 Zarina 
35
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy - - 
1304/
11 
Hashimoto 
Tyroiditis           
49 
Rangana
yaki 
55
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F966
/11 Nodular Goitre 
1326/
11 
Multinodular 
goitre           
50 
Suguna
mma 
45
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F955
/11 
Colloid 
Nodule 
1566/
11 
Multinodular 
goitre           
51 
Nagam
mal 
55
/F 
Solitary 
thyroid 
Nodule 
Total 
Thyroidectom
y 
F111
4/11 
Follicular 
Neoplasm 
1575/
11 
Adenomatous 
Goitre 
10
% 
50
% 
4
0
% 
5
% 
5
% 
52 
Mariam
mal 
60
/F 
Papillary 
Carcinoma 
Thyroid 
Total 
Thyroidectom
y 
F125
0/11 
Papillary 
Carcinoma 
Thyroid 
1723/
11 
Papillary 
Carcinoma 
Thyroid 
10
% 
50
% 
2
0
% 
2
0
% 
1
0
% 
53 
Sundha
mbal 
60
/F 
Solitary 
thyroid 
Nodule 
Subtotal 
Thyroidectom
y 
F971
/11 
Nodular 
Colloid Goitre 
1724/
11 
Multinodular 
goitre           
54 
Ponnula
kshmi 
25
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F125
1/11 Nodular Goitre 
1753/
11 
Adenomatous 
Goitre           
55 Ganesan 
55
/M 
Solitary 
thyroid 
Nodule 
Subtotal 
Thyroidectom
y 
F123
9/11 
Colloid 
Nodule 
1758/
11 
Multinodular 
goitre           
56 
Kantha
mmal 
60
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F125
2/11 
Follicular 
Neoplasm 
1766/
11 
Hyalinising 
Trabecular 
Adenoma 
10
% 
20
% 
2
0
% 
2
0
% 
3
0
% 
57 Gowri 
50
/F 
Solitary 
thyroid 
Hemithyroide
ctomy 
F130
2/11 
Follicular 
Neoplasm 
1870/
11 
Multinodular 
goitre           
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Nodule 
58 
Mohana 
priya 
21
/F 
Solitary 
thyroid 
Nodule 
Neartotal 
Thyroidectom
y 
F126
0/11 Nodular Goitre 
1875/
11 
Hashimoto 
Tyroiditis           
59 
Sangeet
ha 
21
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F127
0/11 
Colloid 
Nodule 
1955/
11 
Hashimoto 
Tyroiditis           
60 
Ponkum
ari 
42
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F129
8/11 Nodular Goitre 
1996/
11 
Multinodular 
goitre           
61 
Anuradh
a 
36
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F130
0/11 
Colloid 
Nodule 
2047/
11 
Multinodular 
goitre           
62 Malathi 
45
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F141
5/11 
Nodular 
Colloid Goitre 
2058/
11 
Adenomatous 
Goitre           
63 Kokila 
25
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F131
4/11 
Nodular 
Colloid Goitre 
2452/
11 
Hashimoto 
Tyroiditis           
64 Kumari 
40
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F150
0/11 
Nodular 
Colloid Goitre 
2197/
11 
Multinodular 
goitre           
65 
Muniya
mmal 
27
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F156
4/11 
Follicular 
Neoplasm 
2290/
11 
Follicular 
Adenoma           
66 
Varathar
ajan 
65
/M 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F155
0/11 
Colloid 
Nodule 
2308/
11 
Multinodular 
goitre           
67 Revathy 
45
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F165
9/11 
Nodular 
Colloid Goitre 
2431/
11 
Multinodular 
goitre           
68 Punitha 
22
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F158
2/11 
Nodular 
Colloid Goitre 
2435/
11 
Adenomatous 
Goitre 
2
% 
70
% 
3
0
% - _ 
69 Mohan 
32
/M 
Cystic 
Nodular 
Goitre 
Total 
Thyroidectom
y 
F910
/11 
Colloid 
Nodule 
234/1
2 
Papillary 
Carcinoma 
Thyroid 
1
% 
90
% 
5
% 
5
%   
70 
Chenna
mmal 
47
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F31/
12 Nodular Goitre 
326/1
2 
multinodular 
goitre           
71 
Chakrav
arthy 
62
/M 
Multinodul
ar Goitre 
Hemithyroide
ctomy _ _ 
859/1
2 Nodular Goitre           
72 
Muniya
mmal 
60
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F542
/12 Nodular Goitre 
979/1
2 
Adenomatous 
Goitre           
73 Mumtaj 
48
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F536
/12 Nodular Goitre 
1020/
12 
Follicular 
Adenoma           
74 Dharani 
40
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F565
/12 Nodular Goitre 
1130/
12 
Multinodular 
goitre           
75 
Yesurat
hinam 
30
/M 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F311
/12 
Colloid 
Nodule 
1269/
12 
Adenomatous 
Goitre           
76 Suguna 
26
/F 
Adenoma 
Thyroid 
Hemithyroide
ctomy 
F 
751/
12 
Adenomatous 
Goitre 
1282/
12 
Follicular 
Adenoma 
1
% 
10
0
% _ _ _ 
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77 Priya 
37
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F730
/12 Nodular Goitre 
1288/
12 
Follicular 
Adenoma 
2
% 
90
% 
5
% 
5
% _ 
78 
Senbaga
m 
35
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F839
/12 
Nodular 
Colloid Goitre 
1435/
12 
Nodular 
Colloid goitre 
with 
Micropapillary 
Hyperplasia           
79 Jaya 
40
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F968
/12 Nodular Goitre 
1648/
12 
Multinodular 
goitre           
80 Pooja 
42
/F 
Cystic 
Nodular 
Goitre 
Hemithyroide
ctomy 
F999
/12 
Nodular 
Colloid Goitre 
1666/
12 
Multinodular 
goitre           
81 Panjali 
40
/F 
Hyperthyro
id 
Subtotal 
Thyroidectom
y - - 
1805/
12 
Hashimoto 
Tyroiditis           
82 
Poongot
hai 
65
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F600
/12 
Colloid 
Nodule 
1902/
12 
Hurthle cell 
adenoma 
5
% 
20
% 
3
0
% 
2
0
% 
3
0
% 
83 Shanthi 
28
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F855
/12 
Colloid 
Nodule 
1965/
12 Nodular Goitre           
84 Selvi 
31
/F 
Follicular 
Adenoma 
Hemithyroide
ctomy 
F116
0/12 
 Follicular 
Neoplasm 
2020/
12 
Follicular 
Adenoma           
85 Sasikala 
50
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F120
2/12 
Nodular 
Colloid Goitre 
2080/
12 
Nodular 
Colloid Goitre           
86 Mariya 
47
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F112
3/12 Nodular Goitre 
2126/
12 
Nodular 
Colloid Goitre           
87 
Pangaja
m 
40
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y - - 
2138/
12 
Multinodular 
goitre           
88 suganthi 
32
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F126
7/12 
Hashimoto 
Thyroiditis 
2180/
12 
Hashimoto 
Tyroiditis           
89 Senthil 
20
/M 
Thyrogloss
al Cyst 
Sistrunk 
Operation 
F124
3/12 
Thyroglossal 
Cyst 
2265/
12 
Thyroglossal 
Cyst           
90 
Chellam
mal 
70
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F118
2/12 
Nodular 
Colloid Goitre 
2274/
12 
Adenomatous 
Goitre           
91 Kumari 
38
/F 
Papillary 
Carcinoma 
Thyroid 
Total 
Thyroidectom
y 
F120
8/12 
Papillary 
Carcinoma 
Thyroid 
2291/
12 
Papillary 
Carcinoma 
Thyroid 
5
% 
40
% 
3
0
% 
2
0
% 
1
0
% 
92 
Jagatha
mbal 
58
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F136
4/12 
Nodular 
Colloid Goitre 
2306/
12 
Nodular 
Colloid Goitre           
93 
Chellam
mal 
50
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F130
1/12 
Colloid 
Nodule 
2323/
12 
Multinodular 
goitre with  
Encapsulated 
Papillary 
Carcinoma  
15
% 
10
% 
4
0
% 
2
0
% 
3
0
% 
94 
Purusho
thaman 
41
/M 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y - - 
2373/
12 
Nodular colloid 
Goitre with 
Micropapillary 
Hyperplasia 
5
% 
20
% 
2
0
% 
4
0
% 
2
0
% 
95 Anjalai 40 Papillary Total F143 Papillary 2441/ Papillary 10 10 5 2 2
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/F Carcinoma 
Thyroid 
Thyroidectom
y 
1/12 Carcinoma 
Thyroid 
12 Carcinoma 
Thyroid 
% % 0
% 
0
% 
0
% 
96 Devagi 
45
/F 
Papillary 
Carcinoma 
Thyroid 
Total 
Thyroidectom
y 
F148
2/12 
Papillary 
Carcinoma 
Thyroid 
2559/
12 
Papillary 
Carcinoma 
Thyroid 
5
% 
30
% 
3
0
% 
3
0
% 
1
0
% 
97 
Kalavat
hi 
32
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F148
5/12 
Nodular 
Colloid Goitre 
2651/
12 
Nodular colloid 
Goitre           
98 
Poornim
a 
27
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F157
9/12 
Colloid 
Nodule 
2674/
12 
Follicular 
Adenoma 
2
% 
50
% 
2
0
% 
5
% 
5
% 
99 
Lourthsa
my 
30
/m 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F134
1/12 
Nodular 
Colloid Goitre 66/13 
Papillary 
Carcinoma 
Thyroid 
10
% 
10
% 
4
0
% 
3
0
% 
2
0
% 
100 
pushpav
alli 
39
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F163
3/12 
Cystic Colloid 
nodule 
108/1
3 
Nodular 
Colloid Goitre           
101 
Unnama
lai 
61
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
192/1
3 
Nodular 
Colloid Goitre           
102 
syed 
jeelani 
24
/M 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy - - 
354/1
3 
Follicular 
Adenoma           
103 
Vijiyala
kshmi 
48
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F122
/13 
Colloid 
Nodule 
384/1
3 Nodular Goitre           
104 Manjula 
38
/F 
Colloid 
Goitre 
Total 
Thyroidectom
y 
F176
/13 Nodular Goitre 
444/1
3 
Nodular 
Colloid Goitre           
105 Girija 
51
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F6/1
3 
Nodular 
Colloid Goitre 
475/1
3 
Nodular 
Colloid Goitre           
106 
Mugund
hani 
20
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
498/1
3 
Hashimoto 
Tyroiditis           
107 
Sandhiy
a 
20
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F206
/13 
Nodular 
Colloid Goitre 
500/1
3 
Follicular 
Adenoma           
108 Uma 
46
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F199
/13 
Hashimoto 
Thyroiditis 
526/1
3 
Hashimoto 
Tyroiditis           
109 
Muniya
mmal 
50
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
547/1
3 
Multinodular 
Goitre           
110 
Muruga
mma 
42
/F 
Nodular 
Goitre 
Total 
Thyroidectom
y - - 
638/1
3 
Nodular 
Colloid Goitre           
111 Parimala 
48
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
652/1
3 
Nodular 
Colloid Goitre           
112 
Magesh
wari 
37
/F 
Papillary 
Carcinoma 
Thyroid 
Total 
Thyroidectom
y 
F359
/13 
Papillary 
Carcinoma 
Thyroid 
659/1
3 
Papillary 
Carcinoma 
Thyroid 
10
% 
10
% 
4
0
% 
3
0
% 
2
0
% 
113 
Kalaisel
vi 
29
/F 
Solitary 
thyroid 
Nodule 
Subtotal 
Thyroidectom
y 
F318
/13 
Nodular 
Colloid Goitre 
675/1
3 
Follicular 
Adenoma 
10
% 
40
% 
3
0
% 
2
0
% 
1
0
% 
114 Malliga 
39
/F 
Solitary 
thyroid 
Total 
Thyroidectom
F385
/13 
Nodular 
Colloid Goitre 
693/1
3 
Nodular colloid 
Goitre           
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Nodule y 
115 Antony 
42
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F326
/13 
Nodular 
Colloid Goitre 
726/1
3 
Hashimoto 
Tyroiditis           
116 
Thilagav
athy 
46
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
795/1
3 
Nodular 
Colloid Goitre           
117 Padmini 
37
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F477
/13 
Nodular 
Colloid Goitre 
980/1
3 
Nodular 
Colloid goitre           
118 
Subbula
kshmi 
34
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
993/1
3 
Adenomatous 
Goitre 
10
% 
58
% 
2
0
% 
1
0
% 
2
% 
119 
Jayapriy
a 
16
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F551
/13 
Nodular 
Colloid Goitre 
999/1
3 
Hashimoto 
Tyroiditis           
120 Kamsala 
46
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F479
/13 
Nodular 
Colloid Goitre 
1005/
13 
Nodular 
Colloid Goitre           
121 Rani 
55
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F369
/13 
Nodular 
Colloid Goitre 
1119/
13 
Nodular colloid 
goitre           
122 Nathiya 
25
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F511
/13 
Follicular 
Neoplasm 
1128/
13 
Adenomatous 
Goitre 
<
1
% 
10
0
% _ _ _ 
123 Devika 
38
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
f632
/13 
Hyperplastic 
nodular Goitre 
1135/
13 
Nodular 
Colloid Goitre           
124 
Saraswa
thi 
30
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F530
/13 
Follicular 
Neoplasm 
1137/
13 
Adenomatous 
Goitre           
125 Pushpa 
84
/F 
Papillary 
Carcinoma 
Thyroid 
Total 
Thyroidectom
y 
F519
/13 
Papillary 
Carcinoma 
Thyroid 
1160/
13 
Papillary 
Carcinoma 
Thyroid 
15
% 
5
% 
4
5
% 
2
0
% 
3
0
% 
126 Anitha 
38
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F597
/13 
Nodular 
Colloid Goitre 
1165/
13 
Nodular colloid 
goitre           
127 Usha 
44
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F659
/13 
Nodular 
Colloid Goitre 
1243/
13 
Nodular colloid 
goitre           
128 
Kalaisel
vi 
41
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F743
/13 
Hashimoto 
Thyroiditis 
1249/
13 
Hashimoto 
Tyroiditis           
129 Mohana  
33
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F578
/13 
Nodular 
Colloid Goitre 
1258/
13 
Follicular 
Adenoma 
5
% 
50
% 
4
0
% 
5
% 
5
% 
130 
Ellizebet
h 
51
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
1369/
13 
Nodular colloid 
goitre           
131 Jothi 
35
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F610
/13 
Hashimoto 
Thyroiditis 
1408/
13 
Hashimoto 
Tyroiditis           
132 Devi 
23
/F 
Solitary 
thyroid 
Nodule 
Total 
Thyroidectom
y 
f630
/13 
Follicular 
Neoplasm 
1439/
13 
Adenomatous 
Goitre 
1
% 
40
% 
1
0
% 
1
0
% 
4
0
% 
133 Sudha 
32
/F 
Familial 
thyroid 
Disease 
Total 
Thyroidectom
y 
F678
/13 
Hyperplastic 
nodular Goitre 
1557/
13 
Nodular colloid 
goitre           
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160 
134 
Ansarbe
e 
28
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F654
/13 
Dominant 
nodule of 
Colloid Goitre 
1565/
13 
Nodular colloid 
goitre           
135 Revathy 
26
/F 
Papillary 
Carcinoma 
Thyroid 
Total 
Thyroidectom
y - - 
1576/
13 
Papillary 
Carcinoma 
Thyroid 
15
% 
55
% 
2
0
% 
1
5
% 
1
0
% 
136 Uma 
21
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F963
/13 
Nodular 
Colloid Goitre 
1620/
13 
Nodular colloid 
goitre           
137 Devaki 
52
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F119
/13 
Dominant 
nodule of 
Colloid Goitre 
1689/
13 
Nodular colloid 
goitre           
138 
Malarko
di 
36
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F102
1/13 
Nodular 
Colloid Goitre 
1695/
13 
Papillary 
Carcinoma 
Thyroid 
5
% 
55
% 
2
0
% 
2
0
% 
5
% 
139 Prema 
47
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F443
/13 
Nodular 
Colloid Goitre 
1710/
13 
Follicular 
Adenoma 
10
% 
40
% 
1
0
% 
2
0
% 
3
0
% 
140 Manjula 
38
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F171
/13 
Nodular 
Colloid Goitre 
1734/
13 
Nodular colloid 
goitre           
141 
Nataraja
n 
70
/M 
Solitary 
thyroid 
Nodule 
Total 
Thyroidectom
y 
F109
7/13 
Nodular 
Colloid Goitre 
1808/
13 
Nodular colloid 
goitre           
142 Andal 
40
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F109
6/13 
Nodular 
Colloid Goitre 
1840/
13 
Nodular colloid 
goitre           
143 Devaki 
42
/F 
Recurrant 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F564
/13 
Hyperplastic 
nodular Goitre 
1186/
13 
Multinodular 
goitre with  
Encapsulated 
Papillary 
Carcinoma  
10
% 
10
% 
4
0
% 
2
0
% 
3
0
% 
144 
Papamm
al 
52
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F141
9/13 
Nodular 
Colloid Goitre 
2359/
13 
Nodular colloid 
goitre           
145 Jayanthi 
53
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F146
4/13 
Nodular 
Colloid Goitre 
2491/
13 
Nodular colloid 
goitre           
146 
Shantha
kumari 
37
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F174
3/13 
Nodular 
Colloid Goitre 
2705/
13 
Nodular colloid 
goitre           
147 Lakshmi 
33
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F158
0/13 
Nodular 
Colloid Goitre 
2750/
13 
Follicular 
Adenoma 
2
% 
20
% 
3
0
% 
4
0
% 
1
0
% 
148 Shantha 
43
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F174
4/13 
Nodular 
Colloid Goitre 
2751/
13 
Papillary 
Carcinoma 
Thyroid 
10
% 
10
% 
3
0
% 
3
0
% 
3
0
% 
149 Nirmala 
31
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F162
1/13 
Nodular 
Colloid Goitre 
2840/
13 
Nodular colloid 
goitre           
150 Eswari 
41
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F167
1/13 
Nodular 
Colloid Goitre 
2842/
13 
Nodular colloid 
goitre           
151 
Mahesh
wari 
52
/F 
Solitary 
thyroid 
Nodule 
Total 
Thyroidectom
y 
F178
4/13 
Nodular 
Colloid Goitre 
2860/
13 
Nodular colloid 
goitre           
152 
Azhagi
meena 
57
/F 
Solitary 
thyroid 
Hemithyroide
ctomy 
F183
7/13 
Follicular 
Neoplasm 
2882/
13 
Follicular 
Adenoma           
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161 
Nodule 
153 lilly 
31
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F184
2/13 
Follicular 
Neoplasm 
2943/
13 
Nodular colloid 
goitre           
154 vatchala 
48
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
2953/
13 
Nodular colloid 
goitre           
155 Malliga 
50
/F 
Thyrogloss
al Cyst 
Sistrunk 
Operation - - 
2990/
13 
Thyroglossal 
Cyst           
156 Kala 
38
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F187
0/13 
Nodular 
Colloid Goitre 
2999/
13 
Nodular colloid 
goitre           
157 
Velanga
ni 
46
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F172
7/13 
Nodular 
Colloid Goitre 66/14 
Nodular colloid 
goitre           
158 
Chandra
kumar 
53
/M 
Colloid 
Goitre 
Hemithyroide
ctomy - - 
235/1
4 
Nodular colloid 
goitre           
159 
Doloros
a 
37
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy - - 
265/1
4 
Colloid Goitre 
with Papillary 
Microcarcinom
a 
10
% 
10
% 
1
0
% 
2
0
% 
6
0
% 
160 Priya 
30
/F 
Solitary 
thyroid 
Nodule 
Total 
Thyroidectom
y 
F182
0/13 
Nodular 
Colloid Goitre 
377/1
4 
Papillary 
Carcinoma 
Thyroid 
10
% 
20
% 
1
0
% 
4
0
% 
3
0
% 
161 
valarmat
hi 
45
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
f155
/14 
Cystic Nodular 
Goitre 
395/1
4 
Nodular colloid 
goitre           
162 
Datchay
ani 
39
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F118
/14 
Cystic Nodular 
Goitre 
433/1
4 
Papillary 
Carcinoma 
Thyroid 
5
% 
10
% 
4
0
% 
3
0
% 
2
0
% 
163 Selvi 
22
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F195
0/13 
Follicular 
Neoplasm 
455/1
4 
Adenomatous 
Goitre           
164 Devi 
23
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F294
/14 
Nodular 
Colloid Goitre 
490/1
4 
Nodular colloid 
goitre           
165 
Krishna
veni 
42
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F30/
14 
Hashimoto 
Thyroiditis 
516/1
4 
Hashimoto 
Tyroiditis 25 
80
% 
2
0
% _ _ 
166 Lakshmi 
55
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F45/
14 
Colloid 
Nodule 
551/1
4 
Nodular colloid 
goitre 
2
% 
65
% 
2
0
% 
1
0
% 
5
% 
167 Devi 
26
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F359
/14 
Nodular 
Colloid Goitre 
590/1
4 
Nodular colloid 
goitre           
168 Shanthi 
28
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F203
/14 
Cystic Nodular 
Goitre 
603/1
4 
Nodular 
Colloid Goitre           
169 
Navama
ni 
32
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F312
/14 
Nodular 
Colloid Goitre 
680/1
4 
Follicular 
Adenoma 
10
% 
20
% 
2
0
% 
2
0
% 
4
0
% 
170 Rani 
50
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F478
/14 
Nodular 
Colloid Goitre 
686/1
4 
Nodular colloid 
goitre           
171 Devi 
33
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F472
/14 
Nodular 
Colloid Goitre 
687/1
4 
Nodular colloid 
goitre           
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
  
162 
172 Priya 
30
/F 
Completion 
Thyoidecto
my 
Total 
Thyroidectom
y 
F470
/14 
Nodular 
Colloid Goitre 
724/1
4 
Nodular colloid 
goitre           
173 
Bakkiya
m 
38
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F410
/14 
Nodular 
Colloid Goitre 
730/1
4 
Nodular colloid 
goitre           
174 Bharathi 
39
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F431
/14 
Nodular 
Colloid Goitre 
734/1
4 
Nodular colloid 
goitre 
1
% 
10
0
% _ _ _ 
175 
Alagara
m 
52
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F506
/14 
Hashimoto 
Thyroiditis 
748/1
4 
Hashimoto 
Tyroiditis 
5
% 
10
0
% _ _ _ 
176 Vijaya 
40
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F427
/14 
Nodular 
Colloid Goitre 
798/1
4 
Nodular colloid 
goitre           
177 Ruby 
39
/F 
Colloid 
Goitre 
Total 
Thyroidectom
y 
F435
/14 
Nodular 
Colloid Goitre 
921/1
4 
Nodular colloid 
goitre           
178 
Raghupa
thy 
28
/M 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F616
/14 
Nodular 
Colloid Goitre 
946/1
4 
Follicular 
Adenoma 
5
% 
60
% 
2
0
% 
1
0
% 
1
0
% 
179 
Dhanala
kshmi 
25
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F630
/14 
Colloid 
Nodule 
967/1
4 
Nodular 
Colloid Goitre           
180 Inkersal 
45
/M 
Solitary 
thyroid 
Nodule 
Total 
Thyroidectom
y 
F700
/14 
Colloid 
Nodule 
993/1
4 
Nodular 
Colloid Goitre           
181 Vijaya 
45
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F557
/14 
Colloid 
Nodule 
1009/
14 
Hashimoto 
Tyroiditis           
182 Bhavani 
37
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F697
/14 
Colloid 
Nodule 
1044/
14 
Follicular 
Adenoma 
2
% 
80
% 
1
0
% 
1
0
% 0 
183 Sushila 
45
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F627
/14 
Nodular 
Colloid Goitre 
1053/
14 
Follicular 
Adenoma 
1
% 
40
% 
1
0
% 
3
0
% 
2
0
% 
184 Selvi 
36
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F691
/14 
Nodular 
Colloid Goitre 
1072/
14 
Nodular 
Colloid Goitre           
185 Ramabai 
49
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F542
/14 
Hashimoto 
Thyroiditis 
1090/
14 
Hashimoto 
Tyroiditis           
186 Selvi 
31
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F780
/14 
Hashimoto 
Thyroiditis 
1126/
14 
Hashimoto 
Tyroiditis           
187 Vanitha 
14
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F714
/14 
Colloid 
Nodule 
1134/
14 
Nodular 
Colloid Goitre           
188 Gowri 
38
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F623
/14 
Nodular 
Colloid Goitre 
1156/
14 
Nodular 
Colloid Goitre           
189 Suguna 
34
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y - - 
1190/
14 
Follicular 
Adenoma 
2
% 
90
% 
5
% 
5
% _ 
190 Udhaya 
36
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F520
/14 
Nodular 
Colloid Goitre 
1221/
14 
Follicular 
Adenoma 
2
% 
50
% 
2
5
% 
2
0
% 
5
% 
191 Jansi 10 Multinodul Total F270 Follicular 1239/ Papillary 15 10 2 2 5
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163 
/F ar Goitre Thyroidectom
y 
1/14 Neoplasm 14 Carcinoma 
Thyroid 
% % 0
% 
0
% 
0
% 
192 
pandidur
ai 
12
/M 
Multinodul
ar Goitre 
Hemithyroide
ctomy 
F655
/14 
Colloid 
Nodule 
1262/
14 
Follicular 
Adenoma 
2
% 
60
% 
2
0
% 
1
0
% 
1
0
% 
193 Lakshmi 
30
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F186
5/13 
Colloid 
Nodule 
1276/
14 
Follicular 
Adenoma 
1
% 
80
% 
1
0
% 
1
0
% _ 
194 Alamelu 
25
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F915
/14 
Nodular 
Colloid Goitre 
1310/
14 
Nodular 
Colloid Goitre           
195 
Rajeswa
ri 
37
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y 
F809
/14 
Colloid 
Nodule 
1380/
14 
Nodular 
Colloid Goitre           
196 
Sadaiya
mmal 
48
/F 
Multinodul
ar Goitre 
Subtotal 
Thyroidectom
y - - 
1392/
14 
Nodular 
Colloid Goitre           
197 
Selvamb
al 
42
/F 
Multinodul
ar Goitre 
Total 
Thyroidectom
y 
F983
/14 
Colloid 
Nodule 
1419/
14 
Follicular 
Adenoma 
2
% 
70
% 
1
0
% 
1
0
% 
1
0
% 
198 
Jayaseel
a 
23
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy 
F901
/14 
Nodular 
Colloid Goitre 
1455/
14 
Nodular 
Colloid Goitre           
199 Kasif 
25
/m 
Multinodul
ar Goitre 
Hemithyroide
ctomy 
F102
8/14 
Benign Cystic 
Lesion 
1542/
14 
Papillary 
Carcinoma 
Thyroid 
10
% 
10
% 
4
0
% 
3
0
% 
2
0
% 
200 Beula  
16
/F 
Solitary 
thyroid 
Nodule 
Hemithyroide
ctomy _ _ 
1567/
14 Nodular Goitre           
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